Get valuable study notes for BS Biotechnology at Mohi-ud-Din Islamic University to excel in your coursework. Helpful tips and key concepts included.pursuing a degree in Biotechnology at Mohi-ud-Din Islamic University can provide you with a solid foundation in the field and prepare you for a successful career in biotechnology. By following the tips outlined in this article and utilizing the study notes provided, you can excel in your academic studies and achieve your educational goals. Good luck in your academic journey!
Study Notes BS Biotechnology at Mohi-ud-Din Islamic University.
INTRODUCTION TO BIOTECHNOLOGY – Complete Study Notes
This comprehensive guide covers the fundamental principles, historical development, core techniques, and applications of biotechnology across medicine, agriculture, industry, and environment. These notes are designed for undergraduate students of biotechnology, life sciences, and related fields.
PART 1: WHAT IS BIOTECHNOLOGY?
1.1 Definition and Scope
Definition: Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. It involves the use of living organisms (microorganisms, plant cells, animal cells) or their components (enzymes) to develop or manufacture useful products.
Key Definitions (Historical):
| Year | Definition | Source |
|---|---|---|
| 1919 | “The use of biological processes for industrial production” | Karl Ereky (Hungarian engineer; coined the term) |
| 1980s | “Any technique that uses living organisms or their products to make or modify a product, improve plants or animals, or develop microorganisms for specific uses” | Office of Technology Assessment (US Congress) |
| 1992 | “The integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular analogues for products and services” | EFB (European Federation of Biotechnology) |
| Modern | “The use of cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet” | Biotechnology Innovation Organization (BIO) |
1.2 Biotechnology Timeline (Historical Development)
| Era | Development | Significance |
|---|---|---|
| 6000 BCE | Fermentation (beer, wine, bread) | First use of microbes (yeast) |
| 4000 BCE | Cheese and yogurt production | Lactic acid bacteria |
| 2500 BCE | Leavened bread (Egypt) | Yeast fermentation |
| 500 BCE | Moldy soybean curds (China) | Early antibiotic use (mold) |
| 1857 | Pasteur’s work on fermentation | Germ theory; microbial metabolism |
| 1897 | Buchner’s cell-free fermentation | Enzymes can function outside cells |
| 1914-1918 | Acetone-butanol fermentation (Weizmann) | Industrial solvents from starch |
| 1928 | Fleming discovers penicillin | Antibiotic era |
| 1940s | Large-scale penicillin production (WWII) | Industrial fermentation |
| 1953 | Watson and Crick discover DNA structure | Molecular biology foundation |
| 1960s | Genetic code deciphered | Understanding of gene expression |
| 1972 | Cohen and Boyer: first recombinant DNA | Birth of genetic engineering |
| 1975 | Kohler and Milstein: monoclonal antibodies | Immunotechnology |
| 1980 | First patent for a microorganism (oil-eating bacterium) | Patent law for biotech |
| 1982 | First recombinant protein (human insulin, Humulin®) | First biotech drug (Eli Lilly) |
| 1983 | First transgenic plant (tobacco) | Plant biotechnology |
| 1988 | First PCR machine | DNA amplification |
| 1990 | First gene therapy trial (ADA-SCID) | Gene therapy |
| 1996 | Dolly the sheep cloned | Cloning (somatic cell nuclear transfer) |
| 2000 | Human Genome Project (draft) | Genomics era |
| 2003 | Human Genome Project completed | Complete human genome sequence |
| 2012 | CRISPR-Cas9 gene editing | Precision genome editing |
| 2019 | COVID-19 mRNA vaccines (Pfizer/BioNTech, Moderna) | RNA therapeutics |
1.3 Color Classification of Biotechnology
| Color | Field | Examples |
|---|---|---|
| Red | Medical biotechnology | Pharmaceuticals, vaccines, gene therapy, diagnostics, regenerative medicine |
| Green | Agricultural biotechnology | Genetically modified crops, biofertilizers, biopesticides, plant tissue culture, molecular breeding |
| White/Gray | Industrial biotechnology | Enzymes, biofuels, bioplastics, biochemicals, fermentation, biocatalysis |
| Blue | Marine biotechnology | Marine-derived drugs, aquaculture, algal biofuels, marine enzymes |
| Yellow | Food biotechnology | Probiotics, fermented foods, food enzymes, food safety testing |
| Gold | Bioinformatics | DNA sequence analysis, protein structure prediction, computational biology |
| Black | Bioweapons and biosecurity | Biological warfare, bioterrorism, biosecurity (often considered negative use) |
| Purple | Patent and legal aspects | Intellectual property, biotech law, regulatory affairs |
PART 2: CORE TECHNIQUES IN BIOTECHNOLOGY
2.1 DNA Replication and PCR
Polymerase Chain Reaction (PCR):
| Component | Purpose | Typical Concentration/Range |
|---|---|---|
| DNA template | Target sequence to be amplified | 10 pg – 1 μg |
| Primers (forward and reverse) | Flank target sequence; provide 3′-OH for polymerase | 0.1-1 μM each |
| dNTPs | Building blocks for new DNA | 200 μM each |
| DNA polymerase (Taq, Pfu, Phusion, Q5) | Synthesizes new DNA; Taq from Thermus aquaticus (thermostable) | 0.5-2 units (U) |
| Buffer | Optimal pH, ionic strength | 1× (manufacturer supplied) |
| Mg²⁺ (or other divalent cation) | Cofactor for DNA polymerase | 1.5-3 mM |
Thermal Cycling Steps:
| Step | Temperature | Time | Purpose |
|---|---|---|---|
| Initial denaturation | 94-98°C | 2-5 min | Fully denature DNA (break H-bonds) |
| Denaturation | 94-98°C | 15-30 sec | Separate strands |
| Annealing | 50-65°C | 15-60 sec | Primers bind to complementary sequences (Tm ~5°C below primer melting temperature) |
| Extension | 72°C | 1 min per kb (for Taq) | Polymerase extends primers |
| Final extension | 72°C | 5-10 min | Complete incomplete extensions |
| Cycles | 25-40 | — | Exponential amplification |
PCR Variants:
| Variant | Purpose | Modification |
|---|---|---|
| RT-PCR | Amplify RNA (cDNA intermediate) | Reverse transcriptase first (RNA → cDNA) |
| qPCR (real-time PCR) | Quantify DNA or RNA | SYBR Green or TaqMan probe (fluorescence monitored each cycle) |
| Nested PCR | Increase specificity | Two rounds of PCR (second with internal primers) |
| Multiplex PCR | Amplify multiple targets simultaneously | Multiple primer pairs in same reaction |
| Inverse PCR | Amplify unknown flanking sequences | Primers oriented outward; circularized template |
| Colony PCR | Screen bacterial colonies for inserts | Directly from colonies (omit DNA extraction) |
2.2 Gel Electrophoresis
| Feature | Agarose Gel Electrophoresis | Polyacrylamide Gel Electrophoresis (PAGE) |
|---|---|---|
| Matrix | Agarose (polysaccharide from seaweed) | Polyacrylamide (cross-linked acrylamide) |
| Pore size | Large (50-500 nm) | Small (10-200 nm) |
| Resolution | Low (distinguishes fragments differing by 100-500 bp) | High (distinguishes fragments differing by 1-2 bp) |
| Range | 100 bp – 20+ kb | 10 bp – 3 kb (DNA) |
| Application | DNA fragment separation (size estimation); PCR product checking | DNA sequencing; protein separation (SDS-PAGE) |
| Staining | Ethidium bromide (EtBr), SYBR Safe, GelRed, methylene blue | Silver staining; Coomassie Blue (proteins); SYBR Gold (DNA) |
2.3 Restriction Enzymes
| Type | Recognition Site | Cut | Requires ATP? | Example |
|---|---|---|---|---|
| Type I | Complex (bipartite) | Random, distant from recognition site (1,000 bp away) | Yes | EcoKI, EcoAI |
| Type II | Palindromic (4-8 bp) | Within recognition site (specific) | No | EcoRI, HindIII, BamHI, SmaI |
| Type III | Asymmetric (bipartite) | Near recognition site (20-30 bp away) | Yes | EcoP15I |
Examples of Type II Restriction Enzymes (Most Commonly Used):
| Enzyme | Source | Recognition Sequence (5’→3′) | Cut Type | Overhang |
|---|---|---|---|---|
| EcoRI | E. coli RY13 | G↓AATTC | Sticky (cohesive) | 5′ overhang (AATT) |
| HindIII | Haemophilus influenzae Rd | A↓AGCTT | Sticky | 5′ overhang (AGCT) |
| BamHI | Bacillus amyloliquefaciens H | G↓GATCC | Sticky | 5′ overhang (GATC) |
| PstI | Providencia stuartii | CTGCA↓G | Sticky | 3′ overhang (TGCA) |
| SmaI | Serratia marcescens | CCC↓GGG | Blunt | — |
| EcoRV | E. coli J62-74 | GAT↓ATC | Blunt | — |
| NotI | Nocardia otitidis-caviarum | GC↓GGCCGC | Sticky | 5′ overhang (GGCC) (rare cutter; 8 bp recognition) |
2.4 Cloning Vectors
| Vector | Insert Size | Features | Use |
|---|---|---|---|
| Plasmid | 0.1-10 kb | Ori (origin of replication), selectable marker (antibiotic resistance), MCS (multiple cloning site) | Gene cloning, expression, subcloning |
| Bacteriophage λ (lambda) | 10-20 kb | Cos sites; packaging into phage heads; linear genome | Genomic libraries |
| Cosmid | 35-45 kb | Plasmid + cos sites (from λ phage) | Large inserts (genomic libraries) |
| BAC (Bacterial Artificial Chromosome) | 100-300 kb | F-factor based; low copy (1-2 per cell) | Genomic libraries, genome projects |
| YAC (Yeast Artificial Chromosome) | 100-2000 kb | Telomeres, centromere, ARS (autonomously replicating sequence) | Large genomic fragments (human genome project) |
| Ti plasmid (Agrobacterium) | Variable | T-DNA (transferred to plant genome); vir genes | Plant transformation |
| Shuttle vector | Variable | Origin for multiple hosts (E. coli + yeast; E. coli + mammalian) | Gene transfer between species |
| Expression vector | Variable | Promoter (inducible: lac, tac, T7, tetracycline, arabinose), terminator, ribosome binding site (RBS, Shine-Dalgarno sequence) | Protein expression |
2.5 DNA Sequencing
Sanger Sequencing (Chain Termination Method):
| Component | Function |
|---|---|
| DNA template | Target sequence |
| Primer | Initiates synthesis |
| DNA polymerase | Extends |
| dNTPs (dATP, dGTP, dCTP, dTTP) | Chain elongation |
| ddNTPs (ddATP, ddGTP, ddCTP, ddTTP, each with different fluorescent dye) | Chain termination (no 3′-OH) |
Principle: Random incorporation of ddNTPs terminates synthesis at different positions → fragments of different lengths; capillary electrophoresis separates fragments by size; laser detects fluorescent dye. Read length: 500-1000 bp.
Next-Generation Sequencing (NGS):
| Platform | Method | Read length | Throughput | Error type | Cost per genome (2024) |
|---|---|---|---|---|---|
| Illumina (SBS) | Reversible dye terminators; bridge amplification | 50-300 bp | Very high (terabases) | Substitutions (phasing errors) | $200-500 (human genome; 30× coverage) |
| Ion Torrent (PGM, Proton) | Semiconductor (pH change from H⁺ release during polymerization) | 200-400 bp | Medium (gigabases) | Indels (homopolymer errors) | $1000-2000 |
| Pacific Biosciences (SMRT) | Single molecule; real-time; zero-mode waveguides | 10-25 kb | Low-medium (gigabases) | Indels (random errors) | $2000-5000 |
| Oxford Nanopore | Protein nanopore; current change as DNA passes through | 10-1000+ kb | Medium (gigabases) | Substitutions, indels | $1000-2000 |
2.6 Blotting Techniques
| Technique | Target | Separation Method | Probe | Application |
|---|---|---|---|---|
| Southern blot | DNA (specific sequence) | Agarose gel electrophoresis | Labeled DNA (complementary) | Gene detection; restriction fragment length polymorphism (RFLP); DNA fingerprinting |
| Northern blot | RNA | Agarose gel electrophoresis (denaturing) | Labeled DNA (complementary) | RNA detection; gene expression; transcript size |
| Western blot | Protein | SDS-PAGE (polyacrylamide gel) | Antibody (primary + secondary labeled antibody) | Protein detection; protein size; post-translational modification analysis |
2.7 Protein Expression and Purification
Host Systems for Recombinant Protein Expression:
| Host | Advantages | Disadvantages | Examples |
|---|---|---|---|
| E. coli | Fast growth; high yield; simple; inexpensive | No eukaryotic post-translational modifications; inclusion bodies (insoluble protein aggregates); endotoxins | Insulin, growth hormone, many enzymes |
| S. cerevisiae (yeast) | Eukaryotic; some post-translational modifications; GRAS (Generally Recognized As Safe) | Over-glycosylation; lower yield than E. coli | Hepatitis B vaccine (surface antigen), insulin, growth factors |
| Pichia pastoris (yeast) | High yield; strong inducible promoter (AOX1, methanol); protein secretion | Methanol required (fire hazard) | Many secreted proteins (enzymes, antigens) |
| Insect cells (baculovirus) | Eukaryotic post-translational modifications; high yield (for some proteins) | Viral infection required; more complex | Complex mammalian proteins (antibodies, receptors) |
| CHO cells (mammalian) | Human-like post-translational modifications; correct folding | Slow growth; expensive; low yield | Therapeutic antibodies (Rituximab, Trastuzumab), complex glycoproteins |
| Plant cells (transgenic plants, plant cell culture) | Low cost; scalable; no animal pathogens | Low yield (often); longer development time | Plant-made pharmaceuticals (PMF) – vaccines, antibodies (e.g., tobacco plants) |
Protein Purification Steps:
| Step | Method | Principle |
|---|---|---|
| Cell lysis | Sonication, French press, bead mill, lysozyme (enzymatic), detergent | Break open cells |
| Clarification | Centrifugation; filtration | Remove cell debris |
| Initial capture | Ammonium sulfate precipitation; ultrafiltration | Concentrate protein; remove some contaminants |
| Ion exchange chromatography (IEX) | Bind protein to charged resin (cation or anion exchange); elute with salt gradient (NaCl) | Separate by net charge |
| Size exclusion chromatography (SEC, gel filtration) | Separate by size (molecular weight); larger proteins elute first | Remove aggregates; buffer exchange |
| Hydrophobic interaction chromatography (HIC) | Bind protein to hydrophobic resin (high salt); elute with decreasing salt gradient | Separate by hydrophobicity |
| Affinity chromatography | Bind protein to specific ligand (antibody, metal ion (Ni²⁺ for His-tag), glutathione (GST tag), protein A (for antibodies)) | Highly specific; high purity |
| Concentration | Ultrafiltration (centrifugal concentrator) | Concentrate final product |
Protein Tags for Affinity Purification:
| Tag | Sequence/Ligand | Elution | Application |
|---|---|---|---|
| Polyhistidine (His-tag) | 6-10 histidines; binds Ni²⁺-NTA resin | Imidazole (10-500 mM) | Most common; small tag; mild elution |
| GST (Glutathione S-transferase) | 26 kDa; binds glutathione resin | Reduced glutathione (10 mM) | High purity; soluble; larger tag |
| FLAG-tag | DYKDDDDK (8 amino acids); binds anti-FLAG antibody | EDTA or low pH | Small tag; specific elution |
| Strep-tag | WSHPQFEK; binds streptavidin | Biotin (or desthiobiotin) | High specificity; mild elution |
| MBP (Maltose Binding Protein) | 40 kDa; binds amylose resin | Maltose (10 mM) | Increases solubility of fusion protein |
PART 3: MEDICAL BIOTECHNOLOGY (RED BIOTECHNOLOGY)
3.1 Biopharmaceuticals
| Type | Examples | Production Host | Indication |
|---|---|---|---|
| Recombinant proteins | Insulin (Humulin®) – 1982 | E. coli | Diabetes |
| Human growth hormone (hGH) – 1985 | E. coli | Growth hormone deficiency | |
| Erythropoietin (EPO, Epogen®) – 1989 | CHO cells | Anemia (kidney disease, chemotherapy) | |
| Interferons (IFN-α, IFN-β, IFN-γ) | E. coli or CHO | Viral infections; multiple sclerosis; cancer | |
| Tissue plasminogen activator (tPA, Activase®) | CHO cells | Acute ischemic stroke; myocardial infarction (clot buster) | |
| Monoclonal antibodies (mAbs) | Rituximab (Rituxan®) – 1997 | CHO cells | Non-Hodgkin lymphoma; rheumatoid arthritis |
| Trastuzumab (Herceptin®) – 1998 | CHO cells | HER2-positive breast cancer | |
| Bevacizumab (Avastin®) – 2004 | CHO cells | Colorectal cancer; lung cancer; glioblastoma | |
| Adalimumab (Humira®) – 2002 (first fully human mAb) | CHO cells | Rheumatoid arthritis; Crohn’s disease; psoriasis | |
| Pembrolizumab (Keytruda®) – 2014 | CHO cells | Cancer (PD-1 inhibitor; immunotherapy) | |
| Vaccines | Hepatitis B vaccine (Recombivax HB®) – 1986 | S. cerevisiae (yeast) | Hepatitis B (recombinant surface antigen) |
| HPV vaccine (Gardasil®) – 2006 | S. cerevisiae | Human papillomavirus (cervical cancer prevention) | |
| COVID-19 mRNA vaccines (Comirnaty® – Pfizer/BioNTech; Spikevax® – Moderna) – 2020 | In vitro transcription (cell-free) | SARS-CoV-2 | |
| COVID-19 viral vector vaccines (AZD1222 – AstraZeneca; Ad26.COV2.S – Johnson & Johnson) – 2020 | HEK293 cells (adenovirus vector) | SARS-CoV-2 | |
| Gene therapy | Luxturna® (RPE65 mutation – inherited blindness) – 2017 | AAV2 vector (recombinant virus) | Leber congenital amaurosis (RPE65 biallelic mutation) |
| Zolgensma® (SMN1 gene for spinal muscular atrophy) – 2019 | AAV9 vector | Spinal muscular atrophy (SMA type 1) | |
| Strimvelis® (ADA-SCID) – 2016 | Retrovirus (ex vivo, autologous CD34⁺ cells) | Adenosine deaminase deficiency (ADA-SCID) | |
| Cell therapy | CAR-T cells (Kymriah® – tisagenlecleucel, Yescarta® – axicabtagene ciloleucel) – 2017 | Patient T cells (ex vivo; lentivirus or retrovirus transduction) | B-cell acute lymphoblastic leukemia; B-cell lymphomas |
3.2 Gene Therapy Approaches
| Approach | Description | Vector | Examples |
|---|---|---|---|
| Ex vivo | Cells removed from patient, modified in lab, returned to patient | Retrovirus, lentivirus (integrating), or CRISPR (non-viral) | ADA-SCID (Strimvelis®); sickle cell disease; beta-thalassemia; CAR-T cells |
| In vivo | Vector injected directly into patient | Adeno-associated virus (AAV; non-integrating), adenovirus (transient), lipid nanoparticles (mRNA) | Luxturna® (AAV, RPE65), Zolgensma® (AAV, SMN1), COVID-19 mRNA vaccines (LNP, not gene therapy but RNA therapeutics) |
3.3 CRISPR-Cas9 Gene Editing
| Component | Function | Source |
|---|---|---|
| Cas9 | Endonuclease (cuts DNA); creates double-strand break (DSB) | Streptococcus pyogenes (most common) |
| guide RNA (gRNA) | Single guide RNA (sgRNA) – fusion of CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) | Synthetic (designed complementary to target) |
| Protospacer adjacent motif (PAM) | Short sequence (NGG for SpCas9) adjacent to target; required for Cas9 recognition | — |
Repair Pathways:
| Pathway | Mechanism | Error-prone? | Outcome | Application |
|---|---|---|---|---|
| Non-homologous end joining (NHEJ) | Joins broken ends directly; small insertions or deletions (indels) | Yes (error-prone) | Gene knockout (frameshift) | Disrupt gene function |
| Homology-directed repair (HDR) | Uses homologous DNA template (donor) for precise repair | No (precise, if donor template provided) | Gene correction; gene insertion (knock-in) | Correct mutation; insert transgene |
PART 4: AGRICULTURAL BIOTECHNOLOGY (GREEN BIOTECHNOLOGY)
4.1 Genetically Modified (GM) Crops
| Trait | Gene(s) | Gene Source | Crop(s) | Effect |
|---|---|---|---|---|
| Herbicide resistance (glyphosate) | cp4 epsps (EPSP synthase) | Agrobacterium sp. CP4 | Soybean, corn, canola, cotton, sugar beet, alfalfa | Tolerant to glyphosate (Roundup®); spray weeds without killing crop |
| Herbicide resistance (glufosinate) | pat or bar (phosphinothricin acetyltransferase) | Streptomyces hygroscopicus (pat), S. viridochromogenes (bar) | Corn, soybean, canola, cotton, rice | Tolerant to glufosinate (Liberty®, Basta®) |
| Insect resistance (Bt crops) | cry1Ab, cry1Ac, cry1F, cry2Ab, cry3Bb, etc. (Cry toxins) | Bacillus thuringiensis (soil bacterium) | Corn (Bt corn), cotton (Bt cotton), soybean, eggplant (Bt brinjal) | Produces insecticidal protein (Cry toxin); effective against Lepidoptera (caterpillars), Coleoptera (beetles), Diptera (flies) |
| Virus resistance | Coat protein (CP) gene | Virus (e.g., Papaya ringspot virus, PRSV) | Papaya (Rainbow, SunUp); squash; potato | Cross-protection (RNA interference; gene silencing) |
| Delayed ripening | Antisense PG (polygalacturonase) or ACC synthase | Tomato | Flavr Savr® tomato (1994; discontinued) | Slows softening; longer shelf life |
| Golden Rice (β-carotene) | psy (phytoene synthase) from daffodil (Narcissus pseudonarcissus) or maize (Zea mays); crtI (phytoene desaturase) from Pantoea ananatis (bacterium) | Rice | Golden Rice (GR2 – developed 2005) | Produces β-carotene (provitamin A); address vitamin A deficiency (VAD) in developing countries |
| Enhanced iron and zinc | Ferritin (soybean), nicotianamine synthase (NAS), ferritin + NAS | Multiple sources | Rice (multi-biofortified) | Increased iron and zinc content |
4.2 Plant Transformation Methods
| Method | Principle | Host | Efficiency | Transgene Integration | Advantages | Disadvantages |
|---|---|---|---|---|---|---|
| Agrobacterium tumefaciens | Natural genetic engineer (Ti plasmid); T-DNA transferred to plant genome | Dicots (most); some monocots (wheat, maize, rice with modifications) | High (for dicots) | Stable (integrated) | Simple; low copy number; stable integration; precise T-DNA borders | Limited to susceptible species (most monocots less susceptible; requires virulence gene induction with acetosyringone) |
| Biolistic (gene gun) | DNA-coated gold or tungsten particles accelerated into plant cells | Wide range (monocots, dicots) | Low-moderate | Stable (integrated) | No host range limitation; can transform multiple copies; can transform organelles (chloroplasts) | Multiple copy insertions (gene silencing); transgene rearrangements; expensive |
| Protoplast transformation (PEG, electroporation) | Chemical (PEG) or electrical (electroporation) uptake of DNA into protoplasts (cell wall removed) | Wide range | Low-moderate | Stable (integrated) | Direct DNA delivery; can be used for transient expression | Protoplast isolation required; regeneration difficult for many species; low efficiency |
4.3 Molecular Markers and Marker-Assisted Selection (MAS)
| Marker Type | Basis | Detection Method | Polymorphism | Advantages | Disadvantages |
|---|---|---|---|---|---|
| RFLP (Restriction Fragment Length Polymorphism) | Restriction site variation | Southern blot (restriction digest + probe hybridization) | Codominant (can distinguish heterozygotes and homozygotes) | Highly reproducible; codominant | Slow; labor-intensive; large DNA required; radioactive probes (historically) |
| RAPD (Random Amplified Polymorphic DNA) | Arbitrary primers (10 bp) amplify random genomic regions | PCR + gel electrophoresis | Dominant (cannot distinguish heterozygotes and homozygotes) | Fast; no sequence information needed | Low reproducibility; dominant markers |
| SSR (Simple Sequence Repeat, microsatellite) | Tandem repeats (2-6 bp); variation in repeat number | PCR + gel electrophoresis or capillary electrophoresis | Codominant | Highly polymorphic; reproducible | Development requires sequence information (primer design) |
| AFLP (Amplified Fragment Length Polymorphism) | Restriction digest + adapter ligation + selective PCR | PCR + gel electrophoresis | Dominant (mostly) | Highly reproducible; no sequence information needed | Technically demanding; dominant (mostly) |
| SNP (Single Nucleotide Polymorphism) | Single base pair changes | Microarray; PCR (allele-specific); genotyping-by-sequencing (GBS); KASP assay | Codominant | Most abundant; high throughput; automatable | Requires sequence information; SNP discovery needed initially |
PART 5: INDUSTRIAL BIOTECHNOLOGY (WHITE BIOTECHNOLOGY)
5.1 Industrial Enzymes
| Enzyme | Source (microbial) | Reaction | Industrial Application |
|---|---|---|---|
| Protease (alkaline) | Bacillus licheniformis, B. subtilis, B. amyloliquefaciens | Hydrolyzes peptide bonds | Detergents (removes protein stains), leather processing (unhairing), food (meat tenderizing), silver recovery (photographic film) |
| Amylase (α-amylase) | Bacillus licheniformis, Aspergillus oryzae | Hydrolyzes α(1→4) bonds in starch (endo-amylase) | Starch liquefaction (ethanol production), desizing textiles, detergents, baking (bread softening) |
| Glucoamylase (amyloglucosidase) | Aspergillus niger, Rhizopus oryzae | Hydrolyzes α(1→4) and α(1→6) from non-reducing end (exo) | Starch saccharification (glucose syrup) |
| Cellulase | Trichoderma reesei, Aspergillus niger | Hydrolyzes cellulose to glucose (β(1→4) linkages) | Cellulosic ethanol; textile finishing (stonewashed jeans); detergents; animal feed |
| Lipase | Candida antarctica, Thermomyces lanuginosus, Aspergillus niger | Hydrolyzes triglycerides → glycerol + fatty acids; also catalyzes esterification, transesterification | Detergents (removes oil stains); biodiesel (transesterification); dairy (flavor development, cheese ripening); baking; pulp and paper |
| Laccase | Trametes versicolor (white-rot fungus), Aspergillus, Myceliophthora | Oxidation of phenols, aromatic amines (O₂ as electron acceptor) | Pulp bleaching (paper industry); textile dye decolorization; bioremediation (lignin degradation) |
| Phytase | Aspergillus niger, E. coli, Trichoderma reesei | Hydrolyzes phytate (inositol hexaphosphate) to phosphate | Animal feed (reduces phosphate pollution; improves phosphorus availability to monogastric animals) |
| Pectinase | Aspergillus niger | Hydrolyzes pectin (α(1→4) galacturonic acid) | Fruit juice clarification (reduces viscosity); wine making; textile degumming (ramie, flax) |
5.2 Biofuels
| Biofuel | Feedstock | Process | Microorganism/Enzyme | Yield | Advantages | Disadvantages |
|---|---|---|---|---|---|---|
| First-generation ethanol | Corn (US), sugarcane (Brazil), wheat (EU), sugar beet, sorghum | Fermentation (sugar → ethanol) | Saccharomyces cerevisiae (yeast) – glucose fermentation (Embden-Meyerhof-Parnas pathway; glycolysis) | 2.5-3.5 gallons/bushel corn; 80-100 L/ton sugarcane | Well-established technology; high yield (from sugar/starch) | Food vs. fuel; land use change (indirect land use change, ILUC); water consumption; net energy balance questionable (for corn ethanol) |
| Second-generation ethanol (cellulosic) | Lignocellulosic biomass (corn stover, wheat straw, rice straw, sugarcane bagasse, wood chips, switchgrass) | Pretreatment (dilute acid, steam explosion, AFEX) → hydrolysis (cellulases, hemicellulases) → fermentation (hexoses and pentoses) | Engineered S. cerevisiae (xylose-fermenting); Zymomonas mobilis; Clostridium thermocellum (consolidated bioprocessing, CBP) | 50-100 gallons/ton biomass | No food competition; uses waste biomass; higher net energy balance | High enzyme cost; pretreatment inhibitors (furfural, HMF, acetic acid, phenolics); pentose fermentation inefficient (engineered strains still lower yield than hexose) |
| Biodiesel | Vegetable oils (soybean, rapeseed, palm, sunflower), animal fats, used cooking oil | Transesterification (triglycerides + methanol → biodiesel (FAME) + glycerol) | Chemical catalyst (NaOH, KOH) or enzyme (lipase, from Candida antarctica, Thermomyces lanuginosus) | 1000 L oil → 1000 L biodiesel + 100 L glycerol | Renewable; biodegradable; lower emissions (CO, hydrocarbons, particulate matter, NOx slightly higher); lubricity (adds lubricity to diesel fuel) | Feedstock cost; glycerol byproduct (low value); cold flow properties (poor at low temperatures); NOx emissions (slightly higher than petroleum diesel) |
| Biogas (methane) | Organic waste (manure, agricultural residue, food waste, sewage sludge) | Anaerobic digestion (hydrolysis → acidogenesis → acetogenesis → methanogenesis) | Microbial consortia (hydrolytic bacteria, acidogenic bacteria, acetogenic bacteria, methanogenic archaea) | 0.5-1 m³ biogas/kg volatile solids (VS) (60-70% CH₄, 30-40% CO₂, trace H₂S, NH₃) | Waste treatment + energy; versatile feedstock | Low energy density (biogas requires purification to biomethane for vehicle fuel); impurities (H₂S corrosive; must be removed); slow process |
| Biobutanol (ABE fermentation) | Starch, sugar, lignocellulosic biomass (after hydrolysis) | Acetone-Butanol-Ethanol (ABE) fermentation | Clostridium acetobutylicum, C. beijerinckii, C. saccharoperbutylacetonicum | 0.25-0.35 g butanol/g glucose | Higher energy density (29.2 MJ/L vs. ethanol 21.2 MJ/L); less volatile; less hygroscopic; can use existing pipelines | Low yield; product inhibition (butanol toxicity to Clostridium at ~15 g/L); strain degeneration (loss of solventogenesis after subculture) |
5.3 Bioplastics
| Type | Monomer | Microorganism | Feedstock | Properties | Applications | Biodegradability |
|---|---|---|---|---|---|---|
| PHB (Poly-3-hydroxybutyrate) | 3-hydroxybutyrate | Cupriavidus necator (formerly Ralstonia eutropha), recombinant E. coli | Glucose, fructose, plant oils (bacterial fermentation) | Brittle; stiff; high crystallinity (similar to polypropylene) | Packaging; compostable bags; single-use items | Biodegradable (soil, marine, compost) |
| PHBV (Copolymer with 3-hydroxyvalerate) | 3-hydroxybutyrate + 3-hydroxyvalerate | C. necator (with propionate as co-substrate) | Glucose + propionate | More flexible; less crystalline than PHB | Films; bottles; medical devices (sutures, scaffolds) | Biodegradable |
| PLA (Polylactic acid) | Lactic acid (from starch fermentation) | Chemical polymerization (not microbial; lactic acid produced by Lactobacillus, then chemically polymerized) | Corn starch, sugarcane, cassava | Biocompatible; transparent; similar to PET (polyethylene terephthalate) | 3D printing filament; food packaging; disposable tableware; sutures; drug delivery | Biodegradable (industrial composting; slow in soil) |
| PCL (Polycaprolactone) | ε-caprolactone (chemical synthesis) | Chemical polymerization |
Microbiology – Comprehensive Study Notes
These notes cover the fundamental principles of microbiology, including the history of microbiology, microbial cell structure, classification, metabolism, growth, control, genetics, and applied microbiology. Suitable for undergraduate students in biology, microbiology, biotechnology, and related fields.
Part 1: Foundations of Microbiology
1.1 What is Microbiology?
Microbiology is the study of microorganisms—living entities that are too small to be seen with the naked eye. These include bacteria, archaea, fungi (yeasts and molds), protozoa, algae, and viruses. Microorganisms are found everywhere: in soil, water, air, on and inside plants and animals, and even in extreme environments such as hot springs, deep-sea vents, and the upper atmosphere.
Taxonomic Groups in Microbiology:
| Group | Cell Type | Examples | Key Characteristics |
|---|---|---|---|
| Bacteria | Prokaryotic | Escherichia coli, Bacillus subtilis, Staphylococcus aureus | Peptidoglycan cell wall; binary fission |
| Archaea | Prokaryotic | Methanogens, Halophiles, Thermophiles | Unique membrane lipids; no peptidoglycan; extremophiles |
| Fungi | Eukaryotic | Saccharomyces cerevisiae (yeast), Aspergillus niger (mold), Agaricus bisporus (mushroom) | Chitin cell walls; heterotrophic; hyphae (filamentous) |
| Protozoa | Eukaryotic | Amoeba, Paramecium, Plasmodium (malaria) | Unicellular, motile (flagella, cilia, pseudopodia); heterotrophic |
| Algae | Eukaryotic | Chlamydomonas, Spirogyra, Diatoms | Photosynthetic; diverse pigments; cellulose cell walls |
| Viruses | Acellular | HIV, influenza virus, bacteriophage T4 | Obligate intracellular parasites; protein coat + nucleic acid |
| Prions | Proteinaceous | PrPᵀⁱⁿᵈ (scrapie, CJD) | Infectious protein; no nucleic acid; causes spongiform encephalopathies |
1.2 History of Microbiology
| Year | Scientist | Contribution |
|---|---|---|
| 1665 | Robert Hooke | Observed cells in cork (first observation of cells) |
| 1674 | Antonie van Leeuwenhoek | First observation of bacteria (“animalcules”) using single-lens microscope |
| 1796 | Edward Jenner | Developed first vaccine (smallpox using cowpox) |
| 1857 | Louis Pasteur | Disproved spontaneous generation; developed pasteurization; developed rabies vaccine; discovered fermentation |
| 1876 | Robert Koch | Demonstrated that Bacillus anthracis causes anthrax; developed Koch’s postulates |
| 1884 | Hans Christian Gram | Developed Gram staining technique (differentiates bacteria by cell wall composition) |
| 1892 | Dmitri Ivanovsky | Discovered viruses (tobacco mosaic virus) |
| 1928 | Alexander Fleming | Discovered penicillin (first antibiotic) |
| 1944 | Avery, MacLeod, McCarty | Demonstrated DNA is the genetic material (transformation experiment) |
| 1977 | Carl Woese | Discovered Archaea (third domain of life) using rRNA sequencing |
1.3 Koch’s Postulates
Koch’s postulates are four criteria used to establish that a specific microorganism causes a specific disease:
-
The microorganism must be present in every case of the disease but absent from healthy individuals
-
The microorganism must be isolated from the diseased host and grown in pure culture
-
The cultured microorganism must cause the same disease when inoculated into a healthy host
-
The same microorganism must be re-isolated from the experimentally infected host
Exceptions: Some pathogens cannot be cultured (viruses, Mycobacterium leprae), some cause disease only in specific hosts, some cause multiple diseases, some are present in healthy carriers.
1.4 Spontaneous Generation Debate
The theory of spontaneous generation held that life arises spontaneously from non-living matter (e.g., maggots from meat, mice from dirty hay). Louis Pasteur definitively disproved spontaneous generation using swan-neck flasks, demonstrating that life arises only from pre-existing life (biogenesis).
Part 2: Microbial Cell Structure
2.1 Prokaryotic vs. Eukaryotic Cells
| Feature | Prokaryotes (Bacteria, Archaea) | Eukaryotes (Fungi, Protozoa, Algae) |
|---|---|---|
| Nucleus | No membrane-bound nucleus | Membrane-bound nucleus (with nuclear envelope) |
| Organelles | No membrane-bound organelles (except some Archaea have membrane-bound compartments?) | Membrane-bound organelles (mitochondria, ER, Golgi, lysosomes, chloroplasts in algae) |
| Cell wall | Peptidoglycan (bacteria); pseudopeptidoglycan or other polymers (Archaea) | Cellulose (algae, plants), chitin (fungi), or absent (protozoa) |
| Ribosomes | 70S | 80S (cytoplasm); 70S in mitochondria/chloroplasts |
| DNA structure | Single circular chromosome; plasmids | Multiple linear chromosomes |
| Histones | Histone-like proteins (not true histones in bacteria; Archaea have histones similar to eukaryotes) | True histones |
| Reproduction | Binary fission (asexual) | Mitosis and meiosis (sexual and asexual) |
| Flagella structure | Made of flagellin (hollow filament) | Made of microtubules (9+2 arrangement) – microtubules not present in prokaryotic flagella |
2.2 Bacterial Cell Structure
General Structure of a Bacterial Cell:
┌─────────────────────────────────────────────────────────────┐
│ Capsule (polysaccharide layer; virulence, attachment) │
│ ┌─────────────────────────────────────────────────────┐ │
│ │ Cell Wall (peptidoglycan) – shape & protection │ │
│ │ ┌─────────────────────────────────────────────┐ │ │
│ │ │ Cell Membrane (phospholipid bilayer) │ │ │
│ │ │ ┌─────────────────────────────────────┐ │ │ │
│ │ │ │ Cytoplasm (ribosomes, nucleoid, │ │ │ │
│ │ │ │ plasmids, inclusions) │ │ │ │
│ │ │ └─────────────────────────────────────┘ │ │ │
│ │ └─────────────────────────────────────────────┘ │ │
│ └─────────────────────────────────────────────────────┘ │
└─────────────────────────────────────────────────────────────┘
↑
Flagella (motility; made of flagellin; basal body, hook, filament)
| Structure | Composition | Function |
|---|---|---|
| Cell membrane | Phospholipid bilayer + proteins | Selective permeability; respiration; transport |
| Cell wall | Peptidoglycan (NAG-NAG cross-linked with peptide bridges) | Structural integrity; shape; prevents osmotic lysis; target of penicillin (inhibits transpeptidase) |
| Capsule (glycocalyx) | Polysaccharide (or polypeptide in some) | Adhesion; protection from phagocytosis; biofilm formation |
| Flagella | Flagellin (protein filament) | Motility (chemotaxis, phototaxis) |
| Pili (fimbriae) | Pilin (protein) | Attachment (fimbriae); conjugation (sex pili – transfer of plasmids) |
| Nucleoid | Circular DNA | Genetic information |
| Plasmids | Extrachromosomal circular DNA | Antibiotic resistance, virulence factors, metabolic capabilities |
| Ribosomes | rRNA + protein (70S) | Protein synthesis |
| Endospores | Keratin-like coat (in some Gram+ bacteria: Bacillus, Clostridium) | Survival under extreme conditions (heat, radiation, chemicals, desiccation) |
Gram-Positive vs. Gram-Negative Cell Walls:
| Feature | Gram-Positive | Gram-Negative |
|---|---|---|
| Peptidoglycan thickness | Thick (20-80 nm) | Thin (2-7 nm) |
| Teichoic acids | Present | Absent |
| Lipopolysaccharide (LPS) | Absent | Present (endotoxin – Lipid A) |
| Outer membrane | No | Yes |
| Periplasmic space | Narrow | Wide |
| Gram stain result | Purple | Pink/red |
| Susceptibility to lysozyme | High (digests peptidoglycan) | Low (outer membrane blocks lysozyme) |
| Susceptibility to penicillin | High (targets peptidoglycan synthesis) | Moderate (outer membrane limits penetration) |
Lipopolysaccharide (LPS):
-
Lipid A (endotoxin – causes fever, inflammation, septic shock)
-
Core polysaccharide
-
O-antigen (O-polysaccharide) – antigenic variability (used for serotyping e.g., E. coli O157:H7)
Flagella Arrangements:
| Arrangement | Description | Example |
|---|---|---|
| Monotrichous | Single flagellum at one pole | Vibrio cholerae |
| Lophotrichous | Tuft of flagella at one or both poles | Pseudomonas fluorescens |
| Amphitrichous | Single flagellum at both poles | Alcaligenes faecalis |
| Peritrichous | Flagella distributed over entire cell | Escherichia coli, Bacillus subtilis |
2.3 Bacterial Shapes and Arrangements
| Shape | Term | Arrangements | Examples |
|---|---|---|---|
| Spherical | Cocci (sing. coccus) | Single, pairs (diplococci), chains (streptococci), clusters (staphylococci), tetrads, sarcinae (cubical packets of 8) | Staphylococcus aureus, Streptococcus pyogenes |
| Rod-shaped | Bacilli (sing. bacillus) | Single, chains (streptobacilli), palisades (side-by-side) | Escherichia coli, Bacillus anthracis |
| Spiral | Spirilla (rigid), Spirochetes (flexible) | Single | Spirillum volutans (spirillum), Treponema pallidum (spirochete – syphilis) |
| Comma-shaped | Vibrio | Single | Vibrio cholerae (cholera) |
| Pleomorphic | Variable shape | Single | Mycoplasma (lack cell wall) |
2.4 Endospores
Endospores are highly resistant, dormant structures formed by some Gram-positive bacteria (Bacillus, Clostridium, Sporosarcina).
Stages of Sporulation (Endospore Formation):
-
Vegetative cell → DNA replicates; septum forms near one pole
-
Forespore engulfed by mother cell (double membrane)
-
Cortex forms (modified peptidoglycan)
-
Coat proteins deposited (keratin-like)
-
Spore matures; mother cell lyses → free endospore
Resistance Properties:
-
Heat resistance (up to 120°C – autoclaving required for sterilization)
-
Resistant to UV radiation, desiccation, chemicals (ethanol, disinfectants)
-
Contains dipicolinic acid (DPA) – stabilizes DNA and proteins
-
Calcium chelation contributes to heat resistance
Germination: Return to vegetative state when conditions become favorable (activation by heat, nutrients).
Examples: Bacillus anthracis (anthrax), Clostridium tetani (tetanus), Clostridium botulinum (botulism), Clostridium perfringens (gas gangrene, food poisoning).
Part 3: Microbial Growth and Nutrition
3.1 Microbial Growth Requirements
| Requirement | Description | Classes Based on Requirement |
|---|---|---|
| Carbon source | Building block for organic molecules | Autotroph (CO₂), Heterotroph (organic carbon) |
| Energy source | ATP production | Phototroph (light), Chemotroph (chemical compounds) |
| Electron source | Reducing power (NADH, NADPH) | Lithotroph (inorganic), Organotroph (organic) |
| Oxygen | For respiration or toxicity | Obligate aerobe, Microaerophile, Facultative anaerobe, Aerotolerant anaerobe, Obligate anaerobe |
| Nitrogen | Amino acids, nucleotides | N₂ fixation (diazotrophs), NH₄⁺, NO₃⁻, organic N |
| Phosphorus | ATP, nucleic acids, phospholipids | PO₄³⁻ |
| Sulfur | Amino acids (cysteine, methionine), cofactors | SO₄²⁻, H₂S, organic S |
| Trace elements | Enzyme cofactors | Fe, Mg, Mn, Zn, Cu, Co, Mo, Ni |
| Growth factors | Organic compounds required for growth | Vitamins, amino acids, purines, pyrimidines (auxotrophs require these; prototrophs synthesize) |
| Temperature | Enzyme activity, membrane fluidity | Psychrophile, Mesophile, Thermophile, Hyperthermophile |
| pH | Proton gradient, enzyme stability | Acidophile, Neutrophile, Alkaliphile |
| Osmotic pressure | Water availability | Halophile (requires salt), Halotolerant (tolerates salt), Osmophile (high sugar) |
3.2 Oxygen Classification
| Class | Oxygen Requirement | Catalase | Superoxide Dismutase (SOD) | Examples |
|---|---|---|---|---|
| Obligate aerobe | Required | Yes | Yes | Bacillus subtilis, Pseudomonas aeruginosa |
| Microaerophile | Required (low O₂ 2-10%) | Yes (but low activity) | Yes | Campylobacter jejuni, Helicobacter pylori |
| Facultative anaerobe | Grows with or without O₂ | Yes | Yes | Escherichia coli, Staphylococcus aureus |
| Aerotolerant anaerobe | Does not use O₂; grows in presence (tolerates) | No (or low) | Yes (or low) | Streptococcus pyogenes (lactic acid bacteria) |
| Obligate anaerobe | Killed by O₂ | No | No | Clostridium botulinum, Bacteroides fragilis |
Reactive Oxygen Species (ROS) and Detoxifying Enzymes:
| ROS | Formation | Toxic effect | Enzyme | Reaction |
|---|---|---|---|---|
| Superoxide radical (O₂⁻) | Incomplete reduction of O₂ | Damages Fe-S clusters | Superoxide dismutase (SOD) | 2O₂⁻ + 2H⁺ → H₂O₂ + O₂ |
| Hydrogen peroxide (H₂O₂) | SOD reaction; oxidases | Oxidizes thiols; forms OH• | Catalase (peroxidase) | 2H₂O₂ → 2H₂O + O₂ (catalase); H₂O₂ + 2H⁺ + 2e⁻ → 2H₂O (peroxidase, using NADH) |
| Hydroxyl radical (OH•) | Fenton reaction (Fe²⁺ + H₂O₂) | Damages DNA, lipids, proteins | No enzymatic defense | Requires prevention (scavengers, repair systems) |
3.3 Temperature Classification
| Class | Temperature Range (°C) | Optimum (°C) | Examples |
|---|---|---|---|
| Psychrophile | -5 to 20 | 10-15 | Polaromonas vacuolata (Antarctic), Psychrobacter |
| Psychrotroph | 0 to 35 | 20-30 | Pseudomonas fluorescens (spoils refrigerated food) |
| Mesophile | 15 to 45 | 30-40 | Escherichia coli (37°C), Bacillus subtilis, human pathogens |
| Thermophile | 40 to 80 | 50-65 | Geobacillus stearothermophilus (used for autoclave testing – biological indicator) |
| Hyperthermophile | 65 to 120 | 80-110 | Pyrolobus fumarii (113°C optimal), Thermus aquaticus (source of Taq polymerase for PCR) |
3.4 pH Classification
| Class | Optimal pH | Examples |
|---|---|---|
| Acidophile | 0.5-3.0 | Acidithiobacillus ferrooxidans (oxidizes Fe²⁺, S⁰; used in bioleaching of copper), Sulfolobus (Archaea) |
| Neutrophile | 6.5-7.5 | Most human pathogens (E. coli, Staphylococcus aureus), many environmental bacteria |
| Alkaliphile | 8.5-11.0 | Bacillus alkalophilus (produces alkaline proteases used in detergents) |
3.5 Bacterial Growth Curve
When bacteria are inoculated into fresh medium, they exhibit a predictable growth pattern with four distinct phases:
| Phase | Description | Characteristics |
|---|---|---|
| Lag Phase | Adaptation to new environment; cells synthesize necessary enzymes and metabolites | No increase in cell number; increase in cell size; metabolic activity high; length depends on nutrient richness and inoculum condition |
| Log (Exponential) Phase | Cells divide at constant maximum rate | Balanced growth; cell number doubles every generation (generation time or doubling time); cells most uniform in size/composition; most sensitive to antibiotics and other stresses; growth rate depends on nutrient availability and environmental conditions |
| Stationary Phase | Growth rate = death rate; cell number constant | Nutrient depletion; waste accumulation; secondary metabolites produced (antibiotics, toxins, pigments); endospore formation begins in some species; stress responses activated |
| Death (Decline) Phase | Death rate exceeds growth rate | Cell number decreases exponentially; cell lysis; some cells persist (persister cells) or form endospores |
Generation Time (Doubling Time): Time required for population to double during log phase.
Mathematical Expression of Exponential Growth:
-
N = N₀ × 2ⁿ (where n = number of generations)
-
N = N₀ × e^(μt) (where μ = specific growth rate constant per hour)
Calculations:
-
n = (log N – log N₀) / log 2 = 3.322 × (log N – log N₀)
-
Generation time (g) = t / n (where t = time of exponential growth)
3.6 Measurement of Microbial Growth
| Method | Principle | Application | Advantages | Disadvantages |
|---|---|---|---|---|
| Direct microscopic count | Count cells in defined volume (Petroff-Hausser counting chamber) | Rapid estimation | Simple, fast; observes morphology | Cannot distinguish live/dead; requires high cell density (>10⁷ cells/mL); motility affects accuracy |
| Viable plate count | Count colony-forming units (CFU) after plating dilutions | Viable cell count | Measures only live cells; sensitive (detects low numbers) | Time-consuming (24-48h incubation); assumes each colony from single cell (may not hold for chains/clumps) |
| Turbidimetric (OD) | Measure light scattering at 600 nm (OD₆₀₀) | Rapid growth estimation | Fast, non-destructive | Measures total cells (live + dead); requires standard curve for calibration; nonlinear at high cell density |
| Dry weight | Filter and weigh biomass | Filamentous organisms, biomass estimation | Direct measure of biomass | Destructive; low sensitivity; time-consuming |
| Flow cytometry | Light scattering and fluorescence of individual cells | Cell counting, viability (dye exclusion), cell sorting | Fast (10⁴-10⁵ cells/sec); multiparameter; distinguishes live/dead | Expensive equipment; requires trained operator |
Viable Plate Count Methods:
-
Spread plate: Sample spread on surface of agar plate (requires absorbent surface)
-
Pour plate: Sample mixed with molten agar then poured into plate (thermally sensitive microbes may be damaged)
-
Membrane filtration: Sample filtered through membrane; membrane placed on agar (for low cell density samples like water analysis)
Part 4: Microbial Metabolism
4.1 Central Carbon Metabolism Pathways
| Pathway | Input | Output | ATP Yield (per glucose) | Location | Organisms |
|---|---|---|---|---|---|
| Glycolysis (EMP pathway) | Glucose | 2 Pyruvate, 2 ATP (net), 2 NADH | 2 ATP (substrate-level phosphorylation) + 2 NADH (→ up to 6 ATP via ETC) | Cytoplasm | Most organisms (bacteria, archaea, eukaryotes) |
| Pentose Phosphate Pathway (PPP) | Glucose-6-P | NADPH, ribose-5-P (nucleotide synthesis), erythrose-4-P (aromatic amino acids) | No ATP; generates NADPH and pentose sugars | Cytoplasm | Many bacteria, eukaryotes |
| Entner-Doudoroff (ED) pathway | Glucose-6-P | 2 Pyruvate, 1 ATP, 1 NADPH, 1 NADH | 1 ATP (net) per glucose | Cytoplasm | Pseudomonas, Zymomonas mobilis, some Archaea |
| TCA (Krebs) cycle | Acetyl-CoA (from pyruvate) | 3 NADH, 1 FADH₂, 1 GTP (ATP), 2 CO₂ | ~10 ATP (via oxidative phosphorylation) | Cytoplasm (prokaryotes); mitochondrial matrix (eukaryotes) | Aerobic organisms |
| Fermentation | Pyruvate (or other organic acids) | Lactic acid, ethanol, CO₂, butyrate, etc. | 2 ATP (substrate-level – from glycolysis) | Cytoplasm | Anaerobic or facultative organisms |
Electron Carriers and Their Roles:
-
NADH: Reduced by catabolic pathways (glycolysis, TCA) → feeds electrons into ETC for oxidative phosphorylation (generates ~2.5-3 ATP per NADH in eukaryotes; variable in prokaryotes)
-
NADPH: Reduced by PPP, some TCA reactions → used in anabolic reactions (biosynthesis, lipid synthesis, detoxification of ROS)
-
FADH₂: Reduced in TCA cycle (succinate dehydrogenase) → feeds electrons into ETC (generates ~1.5-2 ATP per FADH₂)
4.2 Fermentation vs. Respiration
| Feature | Fermentation | Respiration (Aerobic) | Respiration (Anaerobic – using electron acceptors other than O₂) |
|---|---|---|---|
| Electron acceptor | Organic molecule (pyruvate or derivative) | O₂ | Inorganic (NO₃⁻, SO₄²⁻, CO₂, Fe³⁺, etc.) |
| Electron transport chain | No | Yes | Yes |
| ATP yield (per glucose) | 2 ATP (substrate-level phosphorylation only) | Up to 38 ATP (bacterial); ~30-32 ATP (eukaryotic – includes mitochondrial costs) | Variable (less than aerobic) |
| Final products | Lactic acid, ethanol, CO₂, butyric acid, etc. | CO₂ + H₂O | N₂ (denitrification), H₂S (sulfate reduction), CH₄ (methanogenesis), Fe²⁺, etc. |
| Examples | Lactic acid bacteria, yeast (alcoholic fermentation), Clostridium (butyric acid fermentation) | Most aerobes (Bacillus, Pseudomonas, animals, plants) | Pseudomonas (denitrification: NO₃⁻ → N₂), Desulfovibrio (sulfate reduction: SO₄²⁻ → H₂S), Methanobacterium (CO₂ reduction to CH₄ – Archaea) |
Types of Fermentation:
| Type | Organisms | Products | Industrial Use |
|---|---|---|---|
| Lactic acid fermentation (homolactic) | Lactic acid bacteria (Lactobacillus, Streptococcus) | Lactic acid | Yogurt, cheese, sauerkraut, pickles |
| Lactic acid fermentation (heterolactic) | Leuconostoc | Lactic acid + ethanol + CO₂ | Sourdough, some fermented vegetables |
| Alcoholic fermentation | Yeast (Saccharomyces cerevisiae), some bacteria (Zymomonas mobilis) | Ethanol + CO₂ | Bread (CO₂ leavening), beer, wine, bioethanol |
| Mixed acid fermentation | Escherichia coli, Salmonella | Lactic acid, acetic acid, ethanol, CO₂, H₂, formic acid | Used in diagnostic tests (methyl red test) |
| Butyric acid fermentation | Clostridium butyricum | Butyric acid, butanol, acetone, CO₂, H₂ | Production of butanol (ABE fermentation – acetone-butanol-ethanol) |
| Propionic acid fermentation | Propionibacterium | Propionic acid + acetic acid + CO₂ | Swiss cheese (holes from CO₂; propionic acid contributes flavor) |
4.3 Photosynthesis in Microbes
| Type | Oxygen production? | Electron donor | Organisms | Pigments |
|---|---|---|---|---|
| Oxygenic photosynthesis | Yes | H₂O | Cyanobacteria, algae, plants | Chlorophyll a, phycobilins (cyanobacteria), carotenoids |
| Anoxygenic photosynthesis | No | H₂S, H₂, organic compounds | Purple bacteria, green sulfur bacteria, purple non-sulfur bacteria, green non-sulfur bacteria, heliobacteria | Bacteriochlorophyll a, b, c, d, e; carotenoids |
Purple bacteria (Purple sulfur bacteria):
-
Electron donor: H₂S (oxidized to S⁰, then to SO₄²⁻)
-
Pigments: Bacteriochlorophyll a or b, carotenoids (colors: purple, brown, red)
-
Habitat: Anoxic water layers (meromictic lakes, sulfur springs)
-
Example: Chromatium okenii
Green sulfur bacteria:
-
Electron donor: H₂S (oxidized to S⁰ deposited outside cells)
-
Pigments: Bacteriochlorophyll c, d, or e; chlorosomes (light-harvesting structures)
-
Habitat: Anoxic, sulfide-rich environments
-
Example: Chlorobium limicola
Cyanobacteria:
-
Oxygenic photosynthesis (like plants and algae)
-
Pigments: Chlorophyll a, phycobiliproteins (phycocyanin, phycoerythrin, allophycocyanin)
-
Nitrogen fixation in heterocysts (specialized cells in filamentous cyanobacteria, e.g., Anabaena, Nostoc)
-
Examples: Synechococcus, Prochlorococcus (marine picoplankton – major primary producers in oceans)
Part 5: Microbial Genetics
5.1 DNA Structure and Replication
DNA Structure:
-
Double helix (Watson and Crick, 1953)
-
Nucleotides: phosphate, deoxyribose sugar, nitrogenous base (A, T, G, C)
-
Complementary base pairing: A=T, G≡C
-
Antiparallel strands (5’→3′ and 3’→5′)
DNA Replication in Prokaryotes:
-
Origin of replication (oriC): Single origin in bacterial chromosome
-
Bidirectional replication – replication forks proceed in both directions
-
Enzymes:
-
DNA helicase: Unwinds DNA (requires ATP)
-
Primase: Synthesizes RNA primers (short RNA segments)
-
DNA polymerase III: Main replication enzyme (5’→3′ synthesis, 3’→5′ proofreading exonuclease activity)
-
DNA polymerase I: Removes RNA primers and fills gaps (exonuclease activity for primer removal; synthesis)
-
DNA ligase: Joins Okazaki fragments (seals nicks in DNA backbone)
-
-
Leading strand: Continuous synthesis (5’→3′ toward replication fork)
-
Lagging strand: Discontinuous synthesis (Okazaki fragments); fragments joined by ligase
5.2 Gene Expression: Transcription and Translation
Transcription:
-
RNA polymerase synthesizes RNA complementary to DNA template
-
Promoter: DNA sequence where RNA polymerase binds (upstream of gene)
-
Terminator: Signals end of transcription
-
mRNA, tRNA, rRNA synthesized
Translation:
-
Ribosomes (70S in prokaryotes): Site of protein synthesis
-
mRNA: Carries genetic code (codons)
-
tRNA: Carries amino acids (anticodon complementary to mRNA codon)
-
Start codon: AUG (methionine in eukaryotes; N-formylmethionine (fMet) in bacteria)
-
Stop codons: UAA, UAG, UGA
5.3 Genetic Exchange in Bacteria
| Mechanism | Description | Requirements | Genetic outcome | Example |
|---|---|---|---|---|
| Transformation | Uptake of free DNA from environment | Competence (natural or artificial); DNA fragments | New genes integrated into chromosome (if homologous recombination occurs) | Bacillus subtilis, Streptococcus pneumoniae, Haemophilus influenzae; artificial transformation of E. coli using CaCl₂ and heat shock |
| Transduction | Transfer of DNA by bacteriophage | Bacteriophage infection | Phage carries bacterial DNA to new host; generalized transduction (any bacterial gene) or specialized transduction (specific genes near phage integration site) | Salmonella (P22 phage), E. coli (P1 phage generalized; λ phage specialized) |
| Conjugation | Direct cell-to-cell transfer of DNA | Physical contact; conjugative plasmid (e.g., F plasmid) or transposon | Transfer of plasmid (or chromosome if integrated) via sex pilus | E. coli F⁺ × F⁻; transfer of antibiotic resistance plasmids (R factors) |
Plasmid Types:
-
F plasmid (Fertility factor): Conjugative; transfers itself (and may mobilize host chromosome if integrated – Hfr strain)
-
R plasmid (Resistance): Carries antibiotic resistance genes (often multiple resistance genes)
-
Col plasmid: Produces bacteriocins (colicins – kill related bacteria)
-
Metabolic plasmids: Encode catabolic pathways (e.g., degradation of toluene, octane, salicylate)
-
Virulence plasmids: Carry genes for toxins or other virulence factors
Transposons (Jumping Genes):
-
Segments of DNA that can move from one location to another (cut-and-paste or copy-and-paste)
-
Insertion sequences (IS): Simple transposons carrying only transposase gene and inverted repeats
-
Composite transposons (Tn): Carry additional genes (e.g., antibiotic resistance) flanked by IS elements
-
Consequence: Can disrupt genes, cause mutations, mobilize antibiotic resistance genes
5.4 Mutation and DNA Repair
Types of Mutations:
-
Point mutations: Single base pair change
-
Silent mutation: No amino acid change (degeneracy of genetic code)
-
Missense mutation: Changes one amino acid (e.g., sickle cell anemia – Glu6Val in β-globin)
-
Nonsense mutation: Creates stop codon (premature truncation)
-
-
Frameshift mutations: Insertion or deletion (not multiple of 3) – changes reading frame downstream
-
Insertions/deletions (indels): Addition or loss of base pairs
Mutagens:
-
Chemical mutagens: Base analogs (5-bromouracil), alkylating agents (EMS, nitrosoguanidine), intercalating agents (acridine orange, ethidium bromide), nitrous acid (deaminates bases)
-
Physical mutagens: UV light (causes thymine dimers), ionizing radiation (X-rays, γ-rays – causes DNA breaks)
DNA Repair Mechanisms:
| Repair mechanism | Repairs | Key enzymes | Example organism |
|---|---|---|---|
| Photoreactivation | Thymine dimers | Photolyase (uses visible light energy) | Many bacteria, plants, animals (but not humans or placental mammals) |
| Base excision repair (BER) | Small base damage (deamination, alkylation) | DNA glycosylase, AP endonuclease, DNA polymerase, DNA ligase | Widespread |
| Nucleotide excision repair (NER) | Bulky adducts (thymine dimers, BP adducts) | UvrABC complex (bacteria), XP proteins (eukaryotes) | Widespread |
| Mismatch repair (MMR) | Replication errors (mismatched bases) | MutS, MutL, MutH (bacteria); MSH2, MLH1 (eukaryotes) | Widespread |
| Recombinational repair | Double-strand breaks; stalled replication forks | RecA, RecBCD (bacteria); homologous recombination | Widespread |
Part 6: Control of Microbial Growth
6.1 Terminology
| Term | Definition | Method Type |
|---|---|---|
| Sterilization | Destruction or removal of all viable organisms (including endospores and viruses) | Physical/chemical |
| Disinfection | Elimination of pathogens (not necessarily all microbes) from inanimate surfaces | Chemical (disinfectants) |
| Antisepsis | Elimination of pathogens from living tissue (skin, mucous membranes) | Chemical (antiseptics) |
| Sanitization | Reduction of microbial load to safe levels (e.g., food service) | Physical/chemical |
| Pasteurization | Mild heat treatment to kill pathogens and reduce spoilage organisms (not sterilization) | Physical (heat) |
| Degerming | Mechanical removal of microbes from skin (e.g., alcohol swab) | Physical |
| Preservation | Preventing spoilage of food or other materials (e.g., refrigeration, drying, salting, smoking, canning) | Physical/chemical |
6.2 Physical Control Methods
| Method | Mechanism | Effectiveness | Applications |
|---|---|---|---|
| Heat (moist) | Denatures proteins; destroys membranes | Sterilization (autoclave: 121°C, 15 psi, 15-20 min; boiling: disinfection only – kills vegetative cells but not endospores) | Autoclaving: culture media, instruments, waste; boiling: disinfection of instruments |
| Heat (dry) | Oxidation, protein denaturation | Sterilization (oven: 160-170°C for 2-3 hours) | Glassware, metal instruments, powders |
| Pasteurization | Reduces pathogens and spoilage microbes (not sterilization) | 63°C for 30 min (batch) or 72°C for 15 sec (HTST) or 138°C for 2 sec (UHT) | Milk, fruit juices, beer |
| Filtration | Physical removal of microbes | Sterilization (0.22-0.45 µm membrane filters) | Heat-sensitive liquids (serum, antibiotics, vaccines); air filtration (HEPA filters) |
| Radiation (UV) | Damages DNA (thymine dimers) | Disinfection (surface; poor penetration) | Air, water, surfaces (operating rooms, laminar flow hoods) |
| Radiation (ionizing) | DNA breaks (γ-rays, X-rays, electron beams) | Sterilization (penetrating) | Medical supplies (syringes, gloves, sutures); food irradiation |
| Desiccation | Removes water, inhibits growth | Preservation (bacteriostatic) | Food preservation (dried foods: grains, jerky) |
| Osmotic pressure | Plasmolysis (water loss) | Preservation |
MOLECULAR BIOLOGY – Detailed Study Notes
Module 1: The Molecular Basis of Life
1.1 Central Dogma of Molecular Biology (Francis Crick, 1958)
| Direction | Process | Location (Eukaryotes) | Product |
|---|---|---|---|
| DNA → DNA | Replication | Nucleus | DNA (copy) |
| DNA → RNA | Transcription | Nucleus | RNA (mRNA, tRNA, rRNA) |
| RNA → Protein | Translation | Cytoplasm (ribosome) | Protein |
Exceptions to Central Dogma:
-
Reverse transcription (RNA → DNA) – retroviruses (HIV)
-
RNA replication (RNA → RNA) – RNA viruses
-
Prions (Protein → Protein conformation change) – not genetic information flow
1.2 Components of Nucleic Acids
| Component | DNA | RNA |
|---|---|---|
| Sugar | Deoxyribose (H at 2′) | Ribose (OH at 2′) |
| Bases | A, T, G, C | A, U, G, C |
| Strands | Double-stranded (antiparallel) | Usually single-stranded |
| Base pairing | A=T (2 H-bonds), G≡C (3 H-bonds) | A=U, G≡C |
1.3 DNA Double Helix (Watson & Crick, 1953 – based on Franklin’s X-ray data)
| Feature | Description |
|---|---|
| Structure | Two antiparallel polynucleotide strands wound around common axis |
| Diameter | 20 Å (2 nm) |
| Base pairs per turn | 10.5 (B-DNA) |
| Major groove | Wider, accessible for protein binding |
| Minor groove | Narrower |
| Stability | Hydrophobic base stacking (major contributor) + hydrogen bonds |
Module 2: DNA Replication
2.1 General Features
| Feature | Description |
|---|---|
| Semiconservative | Each daughter DNA molecule has one old strand + one new strand (Meselson-Stahl experiment, 1958) |
| Bidirectional | Replication proceeds in both directions from origin |
| Semi-discontinuous | Leading strand continuous; lagging strand discontinuous (Okazaki fragments) |
| Direction | DNA synthesis always 5’→3′ (nucleotide added to 3′-OH) |
2.2 Enzymes and Proteins of DNA Replication (Prokaryotes – E. coli)
| Enzyme/Protein | Function |
|---|---|
| DnaA (initiator protein) | Binds origin (oriC); unwinds AT-rich region |
| Helicase (DnaB) | Unwinds DNA ahead of replication fork (uses ATP) |
| Single-stranded binding protein (SSB) | Stabilizes single-stranded DNA; prevents reannealing |
| Topoisomerase (gyrase) | Relieves supercoiling ahead of fork (cuts, rejoins DNA) |
| Primase (DnaG) | Synthesizes RNA primer (10-12 nucleotides) – provides 3′-OH for DNA polymerase |
| DNA polymerase III | Main replicative polymerase (high processivity – ~1,000 nucleotides/sec in E. coli) |
| DNA polymerase I | Removes RNA primers; fills gaps; has 5’→3′ exonuclease activity |
| DNA ligase | Joins Okazaki fragments (seals nicks) |
2.3 Prokaryotic DNA Replication Steps
| Step | Events |
|---|---|
| Initiation | DnaA binds oriC (245 bp); opens AT-rich region; helicase loaded |
| Primer synthesis | Primase synthesizes RNA primer (both leading and lagging strands initially) |
| Elongation (leading strand) | Pol III adds nucleotides continuously toward replication fork (5’→3′) |
| Elongation (lagging strand) | Pol III adds nucleotides discontinuously away from fork → Okazaki fragments (1,000-2,000 nucleotides in E. coli) |
| Primer removal | Pol I removes RNA primers (5’→3′ exonuclease) and fills gaps with DNA |
| Ligation | DNA ligase joins fragments (ATP or NAD⁺ dependent) |
| Termination | Forks meet at ter sites; Tus protein stops helicase; topoisomerase separates daughter molecules |
2.4 Eukaryotic DNA Replication (Additional Features)
| Feature | Prokaryotes | Eukaryotes |
|---|---|---|
| Origin of replication | Single (oriC) | Multiple (many origins per chromosome) |
| Replicon size | ~1 Mbp | ~100 kbp (per origin) |
| DNA polymerase | Pol III (main); Pol I (primer removal) | Pol α (primer + initiator), Pol δ (leading), Pol ε (lagging), Pol γ (mitochondrial) |
| Primase | DnaG | Part of Pol α complex (primase subunit) |
| Lagging strand maturation | Pol I + ligase | RNase H1 (removes primers) + Pol δ + ligase |
| End replication problem | Not significant (circular DNA) | Linear chromosomes → telomere shortening (solved by telomerase) |
| Cell cycle regulation | Not stringent | Restricted to S phase (cyclin/CDK control) |
2.5 Telomeres and Telomerase
| Feature | Description |
|---|---|
| End replication problem | RNA primer at 5′ end of lagging strand cannot be replaced → chromosome shortens with each replication |
| Telomere | Repetitive DNA sequence (TTAGGG in humans) at chromosome ends – protects from degradation |
| Telomerase | Ribonucleoprotein (RNA component + reverse transcriptase) – adds telomere repeats (not active in most somatic cells; active in germ cells, stem cells, cancer cells) |
| Aging | Telomeres shorten with age (Hayflick limit) |
Module 3: DNA Repair
3.1 Types of DNA Damage
| Damage | Cause | Consequence |
|---|---|---|
| Depurination | Spontaneous (hydrolysis) | Loss of A or G (most common damage) |
| Deamination | Spontaneous (C → U; A → hypoxanthine; 5-methylC → T) | U in DNA (mismatch) |
| Oxidative damage | Reactive oxygen species (ROS) | 8-oxoG (mispairs with A) |
| Alkylation | Chemicals (methylating agents) | Methylated bases (interfere with replication) |
| Pyrimidine dimers | UV light | T-T, C-C, T-C covalent bonds (blocks replication) |
| Double-strand break | Ionizing radiation, chemicals | Most dangerous – chromosome fragmentation |
| Bulky adducts | Carcinogens (benzopyrene) | Blocks transcription, replication |
3.2 DNA Repair Mechanisms
| Mechanism | Damage repaired | Key enzymes/features |
|---|---|---|
| Direct reversal | Pyrimidine dimers (photolyase in some organisms, not humans) | Uses light energy |
| Alkylated guanine (O⁶-methylguanine methyltransferase) | MGMT – suicide enzyme | |
| Base excision repair (BER) | Deamination, depurination, oxidation (single base) | DNA glycosylase (removes base) → AP endonuclease (cuts backbone) → Pol β (adds new base) → ligase |
| Nucleotide excision repair (NER) | Pyrimidine dimers, bulky adducts (~25-30 nucleotides removed) | UvrABC (prokaryotes); XPA-XPG (eukaryotes – xeroderma pigmentosum patients defective in NER) |
| Mismatch repair (MMR) | Replication errors (mismatched base, insertion/deletion loops) | MutS (recognizes mismatch), MutL, MutH (prokaryotes); MSH, MLH (eukaryotes) – hereditary nonpolyposis colorectal cancer (HNPCC/Lynch syndrome) from MMR defects |
| Homologous recombination (HR) | Double-strand breaks (uses sister chromatid as template – error-free) | Rad51 (strand invasion); occurs in S/G2 phase |
| Non-homologous end joining (NHEJ) | Double-strand breaks (direct ligation – error-prone, insertions/deletions) | Ku70/80, DNA-PK, ligase IV; occurs in G1 phase |
Module 4: Transcription (DNA → RNA)
4.1 General Features
| Feature | Description |
|---|---|
| Template strand | DNA strand transcribed (3’→5′) – complementary to RNA |
| Coding strand | Non-template strand (matches RNA sequence except T→U) |
| Direction | RNA synthesis 5’→3′ |
| Nucleotides | ATP, UTP, GTP, CTP |
| Enzyme | RNA polymerase (no primer required) |
4.2 Prokaryotic Transcription (E. coli)
| Component | Function |
|---|---|
| RNA polymerase core | α₂ββ’ω (catalyzes RNA synthesis) |
| Sigma factor (σ) | Recognizes promoter (-10 box/TATAAT and -35 box/TTGACA); directs core to promoter |
| Promoter | DNA sequence where RNA polymerase binds (-10 and -35) |
Steps:
| Phase | Events |
|---|---|
| Initiation | σ factor binds promoter → DNA melts (open complex) → first nucleotides added (no primer) – abortive initiation (short transcripts released) |
| Elongation | σ released (core polymerase elongates); transcription bubble (~18 bp) moves 3’→5′ along template |
| Termination | Rho-independent (intrinsic) – hairpin loop + poly-U sequence → RNA dissociates; Rho-dependent – Rho protein (helicase) binds rut site, catches up to polymerase and releases RNA |
4.3 Eukaryotic Transcription
| Feature | Prokaryotes | Eukaryotes |
|---|---|---|
| RNA polymerases | One (RNA pol) | RNA pol I (rRNA), pol II (mRNA, snRNA), pol III (tRNA, 5S rRNA) |
| Promoters | -10, -35 | Pol II: TATA box (-30), Inr, downstream elements; Pol I/III different |
| Transcription factors | Sigma factor (single) | Many (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH) |
| Chromatin | None (naked DNA) | Nucleosomes must be remodeled (histone acetyltransferases HATs) |
| mRNA processing | Minimal (no introns in most prokaryotes) | Capping, polyadenylation, splicing |
4.4 Transcription in Eukaryotes (Pol II) – Steps
| Phase | Events |
|---|---|
| Initiation | TFIID (TBP) binds TATA box → TFIIA, TFIIB recruit Pol II + TFIIF → TFIIE, TFIIH (helicase, kinase) → open complex → CTD phosphorylation (allows elongation) |
| Elongation | Pol II elongates; nucleosomes displaced (FACT complex); RNA processed co-transcriptionally |
| Termination | Less defined; polyadenylation signal (AAUAAA) triggers cleavage; Pol II continues then terminates (torpedo model) |
Module 5: RNA Processing (Post-transcriptional Modifications)
5.1 Processing of mRNA (Eukaryotes)
| Modification | Location | Enzymes | Function |
|---|---|---|---|
| 5′ cap | 5′ end (7-methylguanosine linked by 5’→5′ triphosphate) | Guanylyltransferase, methyltransferase | Stability, translation initiation, export |
| 3′ polyadenylation | 3′ end (poly-A tail – 100-250 A nucleotides) | Poly-A polymerase | Stability, translation, export |
| Splicing | Removal of introns; joining of exons | Spliceosome (snRNPs: U1, U2, U4, U5, U6) | Alternative splicing (different proteins from same gene) |
5.2 Alternative Splicing
| Definition | Different combinations of exons joined → multiple protein isoforms from single gene |
|---|
| Examples | Tropomyosin (multiple isoforms in muscle vs. non-muscle); DSCAM (38,016 isoforms in Drosophila); human genes (~95% alternatively spliced) |
|---|
5.3 Processing of Other RNAs
| RNA type | Processing | Function |
|---|---|---|
| rRNA | Cleavage (by snoRNPs); methylation; pseudouridylation | Ribosome assembly (nucleolus) |
| tRNA | Cleavage (RNase P – ribozyme); CCA addition; base modifications (inosine, pseudouridine) | Amino acid transfer |
5.4 Ribozymes (Catalytic RNA)
| Example | Reaction |
|---|---|
| RNase P | Cleaves tRNA precursor (ribonucleoprotein – RNA is catalytic component) |
| Self-splicing introns | Group I (Tetrahymena) and Group II introns – splice without spliceosome |
| Ribosome | rRNA catalyzes peptide bond formation (peptidyl transferase) |
Module 6: Translation (mRNA → Protein)
6.1 Components of Translation
| Component | Function |
|---|---|
| mRNA | Template (codons specify amino acids) |
| tRNA | Adapter molecule (carries amino acid; anticodon pairs with codon) |
| Ribosome | Catalyzes peptide bond formation (rRNA = ribozyme) |
| Aminoacyl-tRNA synthetase | Attaches correct amino acid to tRNA (20 synthetases, each specific for one amino acid) |
| Initiation factors (IFs, eIFs) | Assist ribosome assembly |
| Elongation factors (EFs, eEFs) | Deliver aminoacyl-tRNA; translocate ribosome |
| Release factors (RFs) | Recognize stop codons; release polypeptide |
6.2 The Genetic Code
| Feature | Description |
|---|---|
| Triplet code | 3 nucleotides (codon) specify one amino acid |
| Degenerate | Most amino acids have >1 codon |
| Universal | Same code in nearly all organisms (exceptions: mitochondria, some protists) |
| Non-overlapping | Each nucleotide belongs to only one codon |
| Start codon | AUG (methionine – in prokaryotes, formylmethionine) |
| Stop codons | UAA, UAG, UGA (no tRNA; recognized by release factors) |
6.3 tRNA Structure
| Feature | Description |
|---|---|
| Cloverleaf secondary structure | Acceptor stem (3′ CCA – amino acid attached), D-loop, anticodon loop, TψC loop |
| Modified bases | Pseudouridine (ψ), inosine (I – can pair with U, C, or A; wobble) |
| Wobble hypothesis (Crick) | Third base of codon (3′) can pair flexibly with first base of anticodon (5′) – explains degeneracy |
6.4 Ribosome Structure
| Component | Prokaryotes (70S) | Eukaryotes (80S) |
|---|---|---|
| Large subunit | 50S (23S + 5S rRNA + 34 proteins) | 60S (28S, 5.8S, 5S rRNA + 49 proteins) |
| Small subunit | 30S (16S rRNA + 21 proteins) | 40S (18S rRNA + 33 proteins) |
| Sites | A (aminoacyl), P (peptidyl), E (exit) | Same |
Ribozyme activity: 23S rRNA (prokaryotes) / 28S rRNA (eukaryotes) catalyzes peptide bond formation (peptidyl transferase).
6.5 Translation Steps (Prokaryotes)
| Phase | Events |
|---|---|
| Initiation | 30S subunit + IF3 binds mRNA (Shine-Dalgarno sequence – AGGAGGU – pairs with 16S rRNA); IF2 (with GTP) delivers fMet-tRNAᶠᴹᵉᵗ to start codon (AUG); 50S joins (GTP hydrolysis); IFs released |
| Elongation | Aminoacyl-tRNA (AA-tRNA) delivered to A site by EF-Tu (GTP); peptide bond formed (peptidyl transferase – P site amino acid transferred to A site tRNA); EF-G (GTP) translocates ribosome (moves tRNA from A→P, P→E); cycle repeats |
| Termination | Stop codon (UAA, UAG, UGA) in A site; RF1 (UAA/UAG) or RF2 (UAA/UGA) binds; peptide released; ribosome dissociates (RF3, RRF, EF-G) |
6.6 Post-Translational Modifications
| Modification | Function | Examples |
|---|---|---|
| Proteolytic cleavage | Activation (remove propeptide) | Insulin (remove C-peptide); digestive enzymes (trypsinogen → trypsin) |
| Phosphorylation | Regulation (activity, localization) | Kinases, signaling proteins |
| Glycosylation | Folding, stability, recognition | Membrane proteins, secreted proteins |
| Ubiquitination | Targeting for degradation | Proteasome (ATP-dependent) |
| Lipidation | Membrane anchoring | GPI anchors, prenylation |
Module 7: Gene Regulation
7.1 Prokaryotic Gene Regulation – Lac Operon (Jacob & Monod, 1961)
| Component | Function |
|---|---|
| Promoter | RNA polymerase binding site |
| Operator | Repressor binding site |
| Structural genes | lacZ (β-galactosidase), lacY (permease), lacA (transacetylase) |
| Repressor (lacI gene) | Binds operator → blocks transcription (no lactose) |
| Allolactose (inducer) | Binds repressor → repressor releases operator → transcription |
| CAP-cAMP complex | Activator; binds CAP site when glucose low (cAMP high) → enhances transcription |
Conditions:
| Lactose | Glucose | Transcription | Mechanism |
|---|---|---|---|
| – | + | OFF | Repressor bound |
| – | – | OFF | Repressor bound (no inducer) |
| + | + | LOW | Inducer present, repressor off; but CAP not bound (cAMP low) |
| + | – | HIGH | Inducer present; CAP-cAMP bound → strong transcription |
7.2 Eukaryotic Gene Regulation (Levels)
| Level | Mechanism | Description |
|---|---|---|
| Chromatin remodeling | Histone acetylation (HATs) – loosens, activates; deacetylation (HDACs) – tightens, represses | DNA methylation (CpG islands – promoter methylation represses) |
| Transcriptional regulation | Transcription factors (activators bind enhancers, recruit coactivators, Mediator complex); repressors bind silencers | Enhancers can be far (up to 1 Mbp) – looping mediated by cohesin, CTCF |
| RNA processing | Alternative splicing | RNA editing (base modification – A→I, C→U) |
| mRNA stability | AU-rich elements (AREs) in 3′ UTR – destabilize | miRNAs bind mRNA (RISC complex) → degradation or translation block |
| Translational regulation | 5′ UTR secondary structure; upstream ORFs | eIF2 phosphorylation (stress response) |
| Post-translational | Protein modifications (phosphorylation, ubiquitination, etc.) | Protein stability, activity, localization |
Module 8: Molecular Techniques
8.1 PCR (Polymerase Chain Reaction) – Mullis, 1983
| Component | Function |
|---|---|
| DNA template | Target sequence to amplify |
| Primers (forward + reverse) | Define sequence boundaries (18-25 nucleotides) |
| dNTPs | Building blocks |
| Taq DNA polymerase | Heat-stable (from Thermus aquaticus); optimal at 72°C |
| Buffer (MgCl₂) | Cofactor for polymerase |
Cycles:
| Step | Temperature | Time | Purpose |
|---|---|---|---|
| Denaturation | 94-98°C | 20-30 sec | Separate DNA strands |
| Annealing | 50-65°C | 20-30 sec | Primers bind |
| Extension | 72°C | 30 sec – 2 min per kb | DNA synthesis |
Result: Exponential amplification (~2ⁿ copies after n cycles)
Variants:
-
qPCR (real-time PCR) – Quantify DNA using fluorescent dyes (SYBR Green) or probes (TaqMan)
-
RT-PCR – Reverse transcription (RNA → cDNA) then PCR
-
Digital PCR – Absolute quantification (partition into droplets)
8.2 DNA Sequencing
| Method | Principle | Read length | Use |
|---|---|---|---|
| Sanger (dideoxy chain termination) | ddNTPs (lack 3′-OH) terminate synthesis; capillary electrophoresis | 500-1,000 bp | Small projects, confirmatory |
| Next-generation sequencing (NGS) – Illumina | Bridge amplification; reversible terminators; sequencing by synthesis | 100-300 bp (paired end) | Whole genome, RNA-seq, ChIP-seq |
| Third-generation (PacBio, Nanopore) | Single molecule, real-time | >10,000 bp to >100 kbp | De novo assembly, structural variants |
8.3 Blotting Techniques
| Technique | Target | Probe | Detection |
|---|---|---|---|
| Southern blot | DNA | DNA (labeled) | Hybridization |
| Northern blot | RNA | DNA or RNA | Hybridization |
| Western blot | Protein | Antibody (primary + secondary) | Chemiluminescence (HRP) |
8.4 Gene Cloning
| Step | Description |
|---|---|
| 1 | Isolate DNA of interest (PCR or restriction digest) |
| 2 | Cut vector (plasmid) and insert with same restriction enzyme (compatible ends) |
| 3 | Ligate insert into vector (T4 DNA ligase) |
| 4 | Transform into competent bacteria (heat shock or electroporation) |
| 5 | Select on antibiotic plates (ampicillin, kanamycin, etc.) |
| 6 | Screen colonies (blue-white, colony PCR, restriction digest, sequencing) |
8.5 CRISPR-Cas9 (Genome Editing)
| Component | Function |
|---|---|
| Cas9 | Endonuclease (cuts both DNA strands at target site) |
| sgRNA (single guide RNA) | Combines crRNA (target recognition) + tracrRNA (Cas9 binding) – ~20 nucleotides complementary to target |
Mechanism:
-
sgRNA binds Cas9; complex binds target DNA (if PAM sequence NGG present adjacent)
-
Cas9 cuts both strands (3-4 nucleotides upstream of PAM) → double-strand break
-
Repair pathways:
-
Non-homologous end joining (NHEJ) – error-prone → gene knockout (indels)
-
Homology directed repair (HDR) – with donor DNA template → gene knock-in (correction, insertion)
-
Applications: Gene knockout, gene correction (therapy), activation (CRISPRa), repression (CRISPRi), base editing, prime editing
Module 9: Key Terms Glossary
| Term | Definition |
|---|---|
| Central dogma | DNA → RNA → Protein |
| Replication | DNA copies itself (S phase) |
| Transcription | DNA → RNA (in nucleus) |
| Translation | RNA → Protein (ribosome) |
| Okazaki fragment | Discontinuous DNA fragment on lagging strand |
| Telomere | Repetitive DNA at chromosome ends (TTAGGG in humans) |
| Telomerase | Adds telomere repeats (active in germ, stem, cancer cells) |
| Semiconservative | Each daughter DNA has one old + one new strand |
| Intron | Non-coding sequence in pre-mRNA (spliced out) |
| Exon | Coding sequence (retained in mature mRNA) |
| Alternative splicing | Different combinations of exons → multiple protein isoforms |
| Ribozyme | RNA with catalytic activity (RNase P, ribosome, self-splicing introns) |
| Operon | Prokaryotic gene cluster transcribed as single mRNA (lac, trp) |
| Enhancer | Eukaryotic regulatory sequence (activator binding) – far from promoter |
| Promoter | RNA polymerase binding site (initiates transcription) |
| Silencer | Repressor binding site |
| Histone acetylation | Loosens chromatin → activates (HATs) |
| DNA methylation | CpG islands; promoter methylation → represses |
| CRISPR-Cas9 | Genome editing (RNA-guided DNA cutting) |
| PCR | Amplify DNA (polymerase chain reaction) |
| qPCR | Quantitative PCR (real-time) |
| Sanger sequencing | Dideoxy chain termination |
| NGS | Next-generation sequencing (high-throughput) |
Module 10: Sample Exam Questions
Short Answer
-
State the central dogma of molecular biology. List two exceptions.
-
Distinguish between DNA polymerase I and III in E. coli.
-
What is alternative splicing? Why is it important?
-
List the components of the lac operon. What happens when lactose is present but glucose is absent?
-
What is the difference between NHEJ and homologous recombination in double-strand break repair?
Diagram / Label
-
Draw a replication fork. Label helicase, primase, SSB, DNA pol III (leading and lagging), Okazaki fragments, ligase.
-
Draw a tRNA cloverleaf structure. Label acceptor stem, anticodon loop, D-loop, TψC loop.
Essay
-
Describe the process of DNA replication in E. coli (initiation, elongation, termination; all enzymes).
-
Explain transcription in eukaryotes (RNA polymerase II). Include promoter structure, transcription factors, and modifications of pre-mRNA (capping, polyadenylation, splicing).
-
Describe the lac operon. How is it regulated by lactose (inducer) and glucose (catabolite repression)?
-
Compare and describe three DNA repair mechanisms (BER, NER, MMR).
-
Explain how CRISPR-Cas9 works for genome editing. Include the roles of Cas9, sgRNA, PAM sequence, and repair pathways (NHEJ vs. HDR).
Classical Genetics – Complete Study Notes
Classical genetics is the branch of genetics that emerged before the advent of molecular biology, focusing on the transmission of traits from parents to offspring through the mechanisms of inheritance. It is founded on the principle of the gene as the fundamental unit of heredity and uses experimental crosses to deduce how genes are passed from one generation to the next. The foundation of this field was laid by Gregor Mendel in the mid-19th century, and it was later expanded to include concepts of gene linkage, crossing over, and chromosome mapping.
These notes are organized to follow the standard progression of a university-level genetics course, covering Mendelian principles, extensions of Mendelian genetics, probability, linkage analysis, and the chromosomal theory of inheritance.
PART ONE: FOUNDATIONS OF MENDELIAN GENETICS
1.1 Historical Background
Before Mendel, the prevailing theory of inheritance was blending inheritance, which proposed that offspring are a blend, or mixture, of the parental traits. This theory predicted that variation would be diluted out of a population over generations, which contradicted observable natural variation.
Gregor Mendel (1822-1884):
An Austrian monk who conducted systematic hybridization experiments on the garden pea (Pisum sativum) between 1856 and 1863. His work, published in 1865 as “Experiments on Plant Hybridization,” was largely ignored until 1900, when it was independently rediscovered by Hugo de Vries, Carl Correns, and Erich von Tschermak.
Mendel’s Success Factors:
-
Choice of organism: Peas were easy to cultivate, had a short generation time, and produced many offspring
-
Controlled crosses: He could control which plants mated (self-pollination vs. cross-pollination)
-
Discrete traits: He selected seven traits that showed clear, alternative forms (e.g., round vs. wrinkled seeds, yellow vs. green peas)
-
Quantitative analysis: He counted large numbers of offspring and used mathematics to analyze ratios
Key Terms:
| Term | Definition |
|---|---|
| Gene | The fundamental unit of heredity; a segment of DNA that codes for a protein or RNA product |
| Allele | One of two or more alternative forms of a gene (e.g., round vs. wrinkled) |
| Locus (pl. loci) | The specific physical position of a gene on a chromosome |
| Genotype | The genetic makeup of an organism (e.g., Rr) |
| Phenotype | The observable physical or biochemical characteristics of an organism (e.g., round seeds) |
| Homozygous | Having two identical alleles at a locus (e.g., RR or rr) |
| Heterozygous | Having two different alleles at a locus (e.g., Rr) |
| Dominant Allele | An allele that masks the expression of the other allele when present in a heterozygote |
| Recessive Allele | An allele whose expression is masked by a dominant allele in a heterozygote |
1.2 Mendel’s Experimental Design
Mendel followed a systematic approach:
-
Establish true-breeding lines: He allowed plants to self-pollinate for multiple generations to ensure they consistently produced offspring identical to themselves for a given trait (e.g., round-seeded plants always produced round seeds).
-
Perform reciprocal crosses: He crossed two true-breeding lines with contrasting traits and then performed the reciprocal cross (e.g., round-seeded female × wrinkled-seeded male, and wrinkled-seeded female × round-seeded male) to rule out sex-linked or maternal effects.
-
Analyze first-generation (F₁) offspring: He recorded the phenotypes of all offspring.
-
Allow F₁ to self-pollinate: He then allowed the F₁ plants to self-pollinate to produce the second generation (F₂).
-
Quantify F₂ results: He counted the numbers of each phenotype in the F₂ generation and calculated ratios.
Mendel’s Traits in Peas (Seven Traits):
| Trait | Dominant Phenotype | Recessive Phenotype |
|---|---|---|
| Seed shape | Round (R) | Wrinkled (r) |
| Seed color | Yellow (Y) | Green (y) |
| Flower color | Purple (P) | White (p) |
| Pod shape | Inflated (I) | Constricted (i) |
| Pod color | Green (G) | Yellow (g) |
| Flower position | Axial (A) | Terminal (a) |
| Stem length | Tall (T) | Dwarf (t) |
1.3 Mendel’s Laws
Mendel’s First Law: Law of Segregation
The two alleles for a heritable character segregate (separate) during gamete formation, so that each gamete carries only one allele for each gene. This explains the 3:1 phenotypic ratio in the F₂ generation of a monohybrid cross.
Monohybrid Cross Example (Seed Shape):
-
P generation: Round (RR) × Wrinkled (rr)
-
F₁ generation: All round (Rr) – heterozygotes
-
F₂ generation (F₁ × F₁): Rr × Rr → Genotypic ratio: 1 RR : 2 Rr : 1 rr; Phenotypic ratio: 3 round : 1 wrinkled
Punnett Square Analysis:
| R | r | |
|---|---|---|
| R | RR (round) | Rr (round) |
| r | Rr (round) | rr (wrinkled) |
Mendel’s Second Law: Law of Independent Assortment
For two or more genes, the alleles of each gene assort independently of the alleles of other genes during gamete formation. This explains the 9:3:3:1 phenotypic ratio in the F₂ generation of a dihybrid cross.
Dihybrid Cross Example (Seed Shape and Seed Color):
-
P generation: Round, Yellow (RRYY) × Wrinkled, Green (rryy)
-
F₁ generation: All round, yellow (RrYy)
-
F₂ generation (F₁ × F₁): RrYy × RrYy → Phenotypic ratio: 9 round, yellow : 3 round, green : 3 wrinkled, yellow : 1 wrinkled, green
Punnett Square Analysis (simplified):
| RY | Ry | rY | ry | |
|---|---|---|---|---|
| RY | RRYY | RRYy | RrYY | RrYy |
| Ry | RRYy | RRyy | RrYy | Rryy |
| rY | RrYY | RrYy | rrYY | rrYy |
| ry | RrYy | Rryy | rrYy | rryy |
Limitation: Independent assortment only applies to genes located on different chromosomes (or far apart on the same chromosome). Genes on the same chromosome tend to be inherited together (linkage).
PART TWO: EXTENSIONS OF MENDELIAN GENETICS
Not all inheritance patterns follow the simple dominant/recessive, independent assortment model.
2.1 Incomplete Dominance
In incomplete dominance, the heterozygote displays an intermediate phenotype that is distinct from both homozygotes.
Example: Snapdragon (Antirrhinum majus) flower color
-
RR: Red flowers
-
Rr: Pink flowers
-
rr: White flowers
Genotypic and Phenotypic Ratios (F₂): 1 RR (red) : 2 Rr (pink) : 1 rr (white) → 1:2:1 ratio (both genotype and phenotype)
2.2 Codominance
In codominance, both alleles are fully expressed in the heterozygote, resulting in a phenotype that shows both parental traits simultaneously.
Example: ABO blood group system in humans
-
IᴬIᴬ or Iᴬi: Type A blood (A antigens on red blood cells)
-
IᴮIᴮ or Iᴮi: Type B blood (B antigens)
-
IᴬIᴮ: Type AB blood (both A and B antigens) – codominance
-
ii: Type O blood (no A or B antigens) – recessive
Medical Significance: ABO blood groups must be matched for blood transfusions; type O is universal donor; type AB is universal recipient.
2.3 Multiple Alleles
Many genes have more than two possible alleles in a population. However, any single diploid individual can carry at most two alleles.
Example: ABO blood group (three alleles: Iᴬ, Iᴮ, i)
-
Number of possible genotypes: 6 (IᴬIᴬ, Iᴬi, IᴮIᴮ, Iᴮi, IᴬIᴮ, ii)
-
Number of possible phenotypes: 4 (A, B, AB, O)
Example: Rabbit coat color (C gene has multiple alleles)
-
C (full color, dominant) > cᶜʰ (chinchilla) > cʰ (Himalayan) > c (albino, recessive)
2.4 Lethal Alleles
Lethal alleles cause death of the organism when present in a particular genotype (usually homozygous recessive or dominant). They can alter Mendelian ratios.
Example: Yellow coat color in mice (Aʸ allele)
-
AʸA (yellow) × AʸA (yellow) → Expected: 1 AʸAʸ : 2 AʸA : 1 AA
-
Observed: 2 yellow (AʸA) : 1 agouti (AA) : 1 dead (AʸAʸ, lethal in utero)
Example: Manx cat tail (M allele)
-
Mm: Tailless (Manx)
-
MM: Lethal (embryonic death)
-
mm: Normal tail
2.5 Pleiotropy
Pleiotropy occurs when a single gene affects multiple, seemingly unrelated phenotypic traits.
Example: Phenylketonuria (PKU) in humans – mutation in the PAH gene (encodes phenylalanine hydroxylase)
-
Primary effect: Inability to convert phenylalanine to tyrosine, leading to phenylalanine accumulation
-
Secondary effects: Intellectual disability, seizures, fair skin and hair (lack of melanin from reduced tyrosine), musty body odor
Example: Marfan syndrome (FBN1 gene mutation affecting fibrillin-1)
-
Traits: Tall stature, long limbs and fingers, lens dislocation, aortic dilation (increased risk of aortic dissection)
2.6 Epistasis
Epistasis occurs when the expression of one gene (or allele) masks or modifies the expression of another gene at a different locus.
Epistatic vs. Hypostatic:
-
Epistatic gene: The gene that does the masking
-
Hypostatic gene: The gene whose expression is masked
Types of Epistasis:
| Type | Description | F₂ Phenotypic Ratio | Example |
|---|---|---|---|
| Recessive epistasis | Homozygous recessive at one locus masks expression of the other locus | 9:3:4 | Coat color in Labrador retrievers (B/b, E/e): ee (yellow) masks B/b (black/brown) |
| Dominant epistasis | Dominant allele at one locus masks expression of the other locus | 12:3:1 | Fruit color in summer squash (A/a, B/b): A (white) masks B/b (yellow/green) |
| Duplicate recessive epistasis | Homozygous recessive at either of two loci produces same phenotype | 9:7 | Flower color in sweet peas (C/c, P/p): cc or pp produces white flowers |
| Duplicate dominant epistasis | Dominant allele at either of two loci produces same phenotype | 15:1 | Seed capsule shape in shepherd’s purse (Capsella bursa-pastoris) |
| Complementary gene action | Requires dominant alleles at both loci for expression | 9:7 | Same as duplicate recessive epistasis (two genes work together) |
| Inhibitory epistasis | Dominant allele at one locus inhibits expression of dominant allele at the other locus | 13:3 | Feather color in chickens (I/i, C/c): I (inhibitor) prevents color expression |
2.7 Polygenic Inheritance (Quantitative Traits)
Polygenic inheritance occurs when a trait is controlled by two or more genes, each contributing a small additive effect. These traits show continuous variation (not discrete categories).
Characteristics:
-
Quantitative traits: Height, weight, skin color, intelligence, yield in crops
-
Normal distribution: Phenotypes follow a bell-shaped curve
-
Environmental influence: Often strongly influenced by environmental factors
Example: Human skin color – controlled by at least 3-6 genes (e.g., SLC24A5, SLC45A2, MC1R, TYR, OCA2, HERC2), each with “dark” and “light” alleles. The more dark alleles present, the darker the skin (additive effect).
PART THREE: PROBABILITY IN GENETICS
3.1 Product and Sum Rules
The rules of probability are essential for predicting the outcomes of genetic crosses.
Product Rule (Multiplication Rule):
The probability of two or more independent events occurring together is the product of their individual probabilities.
-
Use: “AND” statements (e.g., what is the probability of having a child that is both male AND has blue eyes?)
-
Formula: P(A and B) = P(A) × P(B)
Sum Rule (Addition Rule):
The probability of either of two mutually exclusive events occurring is the sum of their individual probabilities.
-
Use: “OR” statements (e.g., what is the probability of rolling a 2 OR a 3 on a die?)
-
Formula: P(A or B) = P(A) + P(B) (if mutually exclusive)
3.2 Calculating Probabilities in Crosses
Example 1 (Monohybrid Cross): In a cross between two Rr pea plants, what is the probability of obtaining a round-seeded (R_) offspring?
-
Probability of RR = 1/4
-
Probability of Rr = 1/2
-
P(R_) = 1/4 + 1/2 = 3/4
Example 2 (Dihybrid Cross): In a cross between two RrYy pea plants, what is the probability of obtaining an offspring that is round and green (R_ yy)?
-
P(R_) = 3/4
-
P(yy) = 1/4
-
P(R_ yy) = 3/4 × 1/4 = 3/16
Example 3 (Trihybrid Cross): In a cross between two AaBbCc plants, what is the probability of obtaining an Aa Bb Cc offspring?
-
P(Aa) = 1/2
-
P(Bb) = 1/2
-
P(Cc) = 1/2
-
P(Aa Bb Cc) = 1/2 × 1/2 × 1/2 = 1/8
Example 4 (Conditional Probability – Human Pedigree): A couple, both carriers of cystic fibrosis (autosomal recessive, both Aa), have three unaffected children. What is the probability that their fourth child will have cystic fibrosis?
-
The probability for each child is independent: P(aa) = 1/4 regardless of previous children
-
The answer remains 1/4 (previous outcomes do not affect future probabilities)
3.3 Binomial Expansion
Used to calculate the probability of a specific combination of outcomes when the order is not specified.
Binomial Theorem:
P=n!x!(n−x)!pxqn−x
Where:
-
n = total number of events
-
x = number of successes
-
p = probability of success on a single trial
-
q = 1-p = probability of failure on a single trial
Example: In a family of 6 children, what is the probability of having exactly 4 girls?
-
n=6, x=4, p=1/2, q=1/2
-
P=6!4!2!(1/2)4(1/2)2=15×(1/16)×(1/4)=15/64≈0.234
Binomial Expansion of (p + q)ⁿ:
-
For n=3: p³ + 3p²q + 3pq² + q³
-
For n=4: p⁴ + 4p³q + 6p²q² + 4pq³ + q⁴
PART FOUR: TESTING GENETIC HYPOTHESES
4.1 Chi-Square (χ²) Test
The chi-square test is used to determine whether observed data deviate significantly from expected ratios predicted by a genetic hypothesis. It assesses the goodness of fit between observed and expected values.
Formula:
χ2=∑(O−E)2E
Where:
-
O = observed count for each category
-
E = expected count for each category (based on the hypothesis)
Steps for Performing a Chi-Square Test:
-
State the null hypothesis (H₀): There is no significant difference between observed and expected values (i.e., the data fit the predicted ratio).
-
Calculate the expected values: Multiply total offspring by the predicted fraction for each category.
-
Calculate χ²: Sum the squared deviations divided by expected values.
-
Determine degrees of freedom (df): df = number of phenotypic categories – 1 (for a simple goodness-of-fit test).
-
Find the critical value: Use a chi-square distribution table at a chosen significance level (usually α = 0.05).
-
Compare χ² to critical value:
-
If χ² < critical value → Fail to reject H₀ (data fit the hypothesis)
-
If χ² > critical value → Reject H₀ (data do NOT fit the hypothesis)
-
Example: Testing a 3:1 Ratio (Monohybrid Cross)
An F₂ generation from a monohybrid cross yields 84 tall plants and 36 dwarf plants. Does this fit a 3:1 ratio?
-
Total offspring: 84 + 36 = 120
-
Expected tall (3/4): 120 × 3/4 = 90
-
Expected dwarf (1/4): 120 × 1/4 = 30
-
χ² = (84-90)²/90 + (36-30)²/30 = 36/90 + 36/30 = 0.4 + 1.2 = 1.6
-
df = 1 (2 categories – 1)
-
Critical value (α=0.05, df=1): 3.84
-
Conclusion: 1.6 < 3.84 → fail to reject H₀ → data fit a 3:1 ratio
Chi-Square Distribution Table (Critical Values):
| df | α = 0.10 | α = 0.05 | α = 0.01 |
|---|---|---|---|
| 1 | 2.71 | 3.84 | 6.64 |
| 2 | 4.61 | 5.99 | 9.21 |
| 3 | 6.25 | 7.82 | 11.35 |
| 4 | 7.78 | 9.49 | 13.28 |
| 5 | 9.24 | 11.07 | 15.09 |
PART FIVE: PEDIGREE ANALYSIS
Pedigree analysis is the study of inheritance patterns in human families. It is used to determine the mode of inheritance (autosomal dominant, autosomal recessive, X-linked) and to calculate recurrence risks.
5.1 Pedigree Symbols
| Symbol | Meaning |
|---|---|
| □ | Male |
| ○ | Female |
| ◇ | Sex unknown |
| ◼ or ● | Affected individual |
| ◻ or ○ | Unaffected individual |
| ◇ | Deceased |
| ═ | Mating (horizontal line connecting partners) |
| ├─┤ | Consanguineous marriage (related parents) |
| │ | Line connecting parents to offspring |
| I, II, III | Generations (Roman numerals) |
| 1, 2, 3 | Individuals within a generation (Arabic numerals) |
| ▪● | Heterozygote carrier (for autosomal recessive) |
5.2 Modes of Inheritance
| Mode | Key Features | Example Pedigree Pattern |
|---|---|---|
| Autosomal Dominant | Affects both sexes equally; appears in every generation (vertical transmission); affected individuals have at least one affected parent; male-to-male transmission possible | Huntington disease, Marfan syndrome, Achondroplasia |
| Autosomal Recessive | Affects both sexes equally; may skip generations (horizontal transmission); unaffected parents can have affected children; consanguinity increases risk | Cystic fibrosis, Sickle cell anemia, PKU, Tay-Sachs |
| X-Linked Dominant | Affects both sexes, but more females (since males are more severely affected); affected males pass to all daughters (but no sons); affected females pass to 50% of sons and daughters | Vitamin D-resistant rickets (hypophosphatemia) |
| X-Linked Recessive | Affects mostly males (males are hemizygous); unaffected mothers can be carriers; no male-to-male transmission; affected male’s daughters are carriers | Hemophilia A, Duchenne muscular dystrophy, Red-green color blindness |
| Y-Linked (Holandric) | Affects only males; passed from father to all sons; no sons of affected males are unaffected | Hairy ears (rare), SRY gene defects |
| Mitochondrial (Maternal Inheritance) | Passed from mothers to ALL offspring (both sexes); males do not pass to their offspring | Leber hereditary optic neuropathy (LHON), MELAS syndrome |
5.3 Calculating Recurrence Risks
Example 1 (Autosomal Recessive): A couple (both unaffected) has one child with cystic fibrosis (autosomal recessive). What is the probability that their next child will also have cystic fibrosis?
-
Both parents must be carriers (Aa × Aa)
-
P(aa) = 1/4 (regardless of previous children)
Example 2 (X-Linked Recessive): A woman who is a carrier for hemophilia (XᴴXʰ) has a child with an unaffected man (XᴴY). What is the probability that their son will have hemophilia?
-
Sons inherit Y from father and X from mother
-
Probability son inherits Xʰ from mother = 1/2
-
P(affected son) = 1/2
Example 3 (Autosomal Dominant with Incomplete Penetrance): A person has a 60% chance of developing Huntington disease if they carry the HD allele (incomplete penetrance). If a parent has HD (Hh), what is the probability that their child will both inherit the HD allele AND develop the disease?
-
P(inherit H) = 1/2
-
P(develop symptoms | H) = 0.6
-
P(affected) = 1/2 × 0.6 = 0.3 (30%)
PART SIX: LINKAGE AND GENETIC MAPPING
6.1 Linkage
Genes located on the same chromosome tend to be inherited together because they are physically linked. This violates Mendel’s law of independent assortment.
Complete Linkage: Genes located very close together on the same chromosome are always inherited together; parental combinations are maintained.
Incomplete Linkage: Crossing over during prophase I of meiosis can separate linked genes, producing recombinant gametes and offspring.
Recombinant Frequency (RF):
RF=Number of recombinant offspringTotal number of offspring×100%
-
RF = 0% → Complete linkage (no crossing over)
-
RF = 50% → Independent assortment (genes on different chromosomes or far apart on same chromosome)
-
0% < RF < 50% → Incomplete linkage (the smaller the RF, the closer the genes are on the chromosome)
Example (Dihybrid Test Cross for Linkage):
Two genes: seed shape (R/r) and seed color (Y/y) in corn.
-
Parental (P): RRYY (round, yellow) × rryy (wrinkled, green)
-
F₁: RrYy (round, yellow)
-
Test cross: RrYy × rryy
-
If independent assortment: Expected 1:1:1:1 ratio (RY, Ry, rY, ry)
-
If linkage observed: Parental types (RY and ry) > recombinant types (Ry and rY)
6.2 Genetic Mapping (Recombination Mapping)
The principle of linkage mapping (also called recombination mapping) is that the frequency of recombination between two genes is proportional to the distance between them on the chromosome. One map unit (m.u.) or centiMorgan (cM) corresponds to a 1% recombination frequency.
Mapping Function (for small distances):
Distance (cM)=RF×100
Example: In a test cross between AaBb and aabb, if RF = 12%, then the distance between A and B is 12 cM.
6.3 Three-Point Test Cross
A three-point test cross involves three linked genes simultaneously. It is used to determine:
-
Gene order
-
Distances between genes
-
Interference and coefficient of coincidence
Steps for Three-Point Mapping:
-
Cross triply heterozygous (AaBbCc) with triply recessive (aabbcc)
-
Count offspring phenotypes
-
Identify the two most abundant classes (parental types)
-
Identify the two least abundant classes (double crossovers, DCOs)
-
Determine gene order: the gene that changes position between parental and DCO classes is the middle gene
-
Calculate distances: (SCO + DCO)/Total × 100 for each interval
-
Calculate interference: I = 1 – (observed DCO / expected DCO)
Coefficient of Coincidence (COC):
COC=Observed double crossoversExpected double crossovers
Interference (I):
I=1−COC
Interpretation:
-
I=0 → No interference (double crossovers occur as predicted)
-
I=1 → Complete interference (no double crossovers occur)
-
I>0 → Positive interference (fewer DCOs than expected)
6.4 Mitotic vs. Meiotic Crossing Over
-
Meiotic crossing over: Occurs during prophase I of meiosis; produces recombinant gametes; basis of genetic mapping
-
Mitotic crossing over: Rare event in somatic cells; can produce twin spots (two patches of homozygous recessive tissue in an otherwise heterozygous organism); used in fungal genetics (e.g., Aspergillus nidulans)
PART SEVEN: CHROMOSOMAL THEORY OF INHERITANCE
7.1 Key Contributors
| Scientist(s) | Contribution | Year(s) |
|---|---|---|
| Walter Sutton | Proposed that genes are located on chromosomes (Sutton-Boveri Theory) | 1902 |
| Theodor Boveri | Demonstrated that chromosomes are the carriers of heredity | 1902 |
| Thomas Hunt Morgan | Demonstrated linkage and crossing over using Drosophila melanogaster; established that genes are arranged linearly on chromosomes | 1910-1915 |
| Alfred Sturtevant | Constructed the first genetic map (of the X chromosome of Drosophila) | 1911 |
| Calvin Bridges | Demonstrated non-disjunction, providing proof that chromosomes carry genes | 1916 |
| Barbara McClintock | Discovered transposons (“jumping genes”) using maize | 1940s-1950s |
| Harriet Creighton & Barbara McClintock | Demonstrated that crossing over involves physical exchange between homologous chromosomes | 1931 |
7.2 Nondisjunction
Nondisjunction is the failure of homologous chromosomes (meiosis I) or sister chromatids (meiosis II) to separate properly during cell division, resulting in gametes with an abnormal number of chromosomes (aneuploidy).
| Condition | Chromosome Complement | Example Syndrome |
|---|---|---|
| Monosomy | Missing one chromosome (2n-1) | Turner syndrome (XO) |
| Trisomy | One extra chromosome (2n+1) | Down syndrome (Trisomy 21), Edwards (Trisomy 18), Patau (Trisomy 13) |
| Tetrasomy | Two extra chromosomes (2n+2) | Tetrasomy X (XXXX), Tetrasomy 18p |
| Nullisomy | Missing a homologous pair (2n-2) | Lethal in most cases |
Calvin Bridges’ Nondisjunction Experiment (1916):
-
Cross: XᴡXᴡ (white-eyed female) × XʸY (red-eyed male) → Expected: XᴡY (white males), XᴊXᴡ (red females)
-
Observed: occasional white-eyed females and red-eyed males
-
Explanation: Nondisjunction in the female produced eggs with two Xs (XᴡXᴡ) or no X, resulting in XXY (white females, fertile) and XO (red males, sterile)
7.3 Sex Chromosomes and Sex Determination
| System | Female | Male | Examples |
|---|---|---|---|
| XY (Male heterogametic) | XX | XY | Humans, most mammals, Drosophila (but dosage compensation differs) |
| ZW (Female heterogametic) | ZW | ZZ | Birds, some reptiles, butterflies, some fish (e.g., zebrafish) |
| XO | XX | XO | Grasshoppers, some insects, some nematodes (C. elegans hermaphrodite XX, male XO) |
| Haplodiploid | Diploid (2n) | Haploid (n) | Bees, wasps, ants (Hymenoptera) |
Sex Determination in Humans:
-
SRY (Sex-determining Region Y) gene on the Y chromosome (present in approximately 99% of males)
-
SRY encodes testis-determining factor (TDF) → triggers development of testes → testosterone → male reproductive tract
-
In the absence of SRY → ovaries develop → female reproductive tract
QUICK REFERENCE: SUMMARY TABLES
Summary of Mendelian Ratios
| Cross Type | Genotypic Ratio | Phenotypic Ratio | Notes |
|---|---|---|---|
| Monohybrid cross (Aa × Aa) | 1 AA : 2 Aa : 1 aa | 3 dominant : 1 recessive | Simple dominance |
| Monohybrid test cross (Aa × aa) | 1 Aa : 1 aa | 1 dominant : 1 recessive | – |
| Incomplete dominance (Rr × Rr) | 1 RR : 2 Rr : 1 rr | 1:2:1 | Each genotype has distinct phenotype |
| Dihybrid cross (AaBb × AaBb) | 1 AABB : 2 AABb : … (9 genotypes) | 9:3:3:1 | Independent assortment, no linkage |
| Dihybrid test cross (AaBb × aabb) | 1 AaBb : 1 Aabb : 1 aaBb : 1 aabb | 1:1:1:1 | Independent assortment |
| Trihybrid cross (AaBbCc × AaBbCc) | 27 genotypes | 27:9:9:9:3:3:3:1 | 8 phenotypic classes (2³) |
Summary of Epistatic Ratios
| Type | F₂ Ratio | Description |
|---|---|---|
| Recessive epistasis | 9:3:4 | aa masks B/b |
| Dominant epistasis | 12:3:1 | A masks B/b |
| Duplicate recessive epistasis | 9:7 | aa or bb produces same phenotype |
| Duplicate dominant epistasis | 15:1 | A or B produces same phenotype |
| Inhibitory epistasis | 13:3 | Inhibitor (I) masks C |
GLOSSARY OF KEY TERMS
| Term | Definition |
|---|---|
| Allele | Alternative form of a gene at a specific locus |
| Backcross | Cross between F₁ and either parent |
| Centimorgan (cM) | Unit of genetic map distance; 1 cM = 1% recombination frequency |
| Chi-square (χ²) test | Statistical test for goodness of fit between observed and expected data |
| Codominance | Both alleles expressed in heterozygote (e.g., AB blood type) |
| Crossing over | Exchange of genetic material between homologous chromosomes during prophase I |
| Dihybrid cross | Cross involving two genes |
| Epistasis | Interaction where one gene masks expression of another gene |
| F₁ generation | First filial generation; offspring of P generation |
| F₂ generation | Second filial generation; offspring from crossing F₁ individuals |
| Genotype | Genetic constitution of an organism |
| Hemizygous | Having only one copy of a gene (e.g., X-linked genes in males) |
| Heterozygote | Having two different alleles at a locus |
| Homozygote | Having two identical alleles at a locus |
| Incomplete dominance | Heterozygote has intermediate phenotype |
| Independent assortment | Mendel’s second law; alleles of different genes assort independently during gamete formation |
| Linkage | Tendency of genes on the same chromosome to be inherited together |
| Locus | Physical position of a gene on a chromosome |
| Map unit (m.u.) | Unit of genetic distance; 1 m.u. = 1% recombination frequency |
| Monohybrid cross | Cross involving one gene |
| P generation | Parental generation; first cross in an experiment |
| Pedigree | Family tree showing inheritance patterns |
| Phenotype | Observable characteristics of an organism |
| Pleiotropy | Single gene affects multiple phenotypic traits |
| Polygenic inheritance | Trait controlled by multiple genes; continuous variation |
| Punnett square | Grid used to predict genotypic and phenotypic ratios of offspring |
| Recombinant | Offspring with a different combination of alleles than either parent |
| Segregation | Mendel’s first law; separation of alleles during gamete formation |
| Test cross | Cross between a dominant-phenotype individual (unknown genotype) and a homozygous recessive individual |
| Wild type | Most common phenotype in a natural population |
SAMPLE EXAMINATION QUESTIONS
Short Answer Questions:
-
Distinguish between genotype and phenotype. Provide an example of each using Mendel’s pea traits.
-
What is the expected phenotypic ratio in the F₂ generation of a dihybrid cross if the two genes are unlinked? What ratio would indicate linkage?
-
A woman with type A blood (Iᴬi) and a man with type B blood (Iᴮi) have a child. What is the probability that their child will have type O blood? Type AB blood?
-
In Labrador retrievers, coat color is controlled by two genes: B/b (black/brown) and E/e (pigment deposition). The e/e genotype produces yellow regardless of the B/b genotype. What is the F₂ phenotypic ratio from a cross between a black lab (BBEE) and a yellow lab (bbee)?
-
What is the difference between a monohybrid cross and a test cross? In what situation would a test cross be used?
Genetic Engineering – Study Notes
1. Core Concepts & Scope
-
Genetic Engineering (also called Genetic Modification): The deliberate, controlled manipulation of an organism’s genes using biotechnology. It involves the direct alteration of an organism’s genome by introducing, deleting, or modifying specific DNA sequences to achieve a desired trait .
-
Key Distinction: Unlike traditional cross-breeding, which mixes thousands of genes unpredictably between closely related species, genetic engineering allows for the precise transfer of one or a few specific, well-characterized genes from any organism (even across species barriers) into another. This creates a transgenic (Genetically Modified/GM) organism .
-
Why Genetic Engineering Matters:
-
Medicine: Production of human insulin, growth hormone, vaccines (Hepatitis B), and therapeutic antibodies; gene therapy for genetic disorders (e.g., SCID, sickle cell disease).
-
Agriculture: Crops with pest resistance (Bt cotton/maize), herbicide tolerance (Roundup Ready® soybeans), enhanced nutrition (Golden Rice), and longer shelf life (Flavr Savr tomato).
-
Industry: Production of enzymes (e.g., chymosin for cheese-making), biofuels, bioplastics, and specialty chemicals.
-
Research: Creation of transgenic animal models (mice, zebrafish) to study human diseases (cancer, Alzheimer’s) and gene function (knockout/knock-in mice).
-
Environmental: Bacteria engineered to degrade oil spills (bioremediation), detect heavy metals, or produce biodegradable plastics.
-
The Central Dogma & Genetic Engineering
Genetic engineering works by intervening in the flow of genetic information:
DNA (Gene)→TranscriptionmRNA→TranslationProtein→Trait
-
Goal: To alter the protein(s) produced and, therefore, the resulting trait.
-
Methods to Alter the Flow:
-
Insert a new gene (from another organism) to produce a new protein (e.g., Bt toxin gene in cotton).
-
Knock out (disrupt) an existing gene to prevent a protein from being made (e.g., knockout of the myostatin gene to increase muscle mass).
-
Edit (modify) an existing gene to change its protein product (e.g., correcting a point mutation in the CFTR gene for cystic fibrosis).
-
Change gene regulation (e.g., inserting a stronger promoter to increase protein production).
-
2. Foundational Tools of Genetic Engineering
The ability to manipulate DNA relies on a set of essential molecular tools. These are often called the “molecular scissors, glue, and copy machine.”
A. Restriction Enzymes (Molecular Scissors)
-
Source: Bacteria (part of their defense system against bacteriophages).
-
Function: Recognize and cut DNA at very specific, short palindromic sequences (typically 4-8 base pairs). This produces a “restriction map.”
-
Types of Cuts:
-
Blunt Ends: Cut straight across both strands (e.g., SmaI).
-
Sticky (Cohesive) Ends: Cut in a staggered pattern, producing short, single-stranded overhangs. These are extremely useful for cloning because they easily pair with complementary sticky ends from other DNA molecules cut with the same enzyme.
-
-
Naming Convention: Named after the bacterium they are isolated from (e.g., EcoRI from Escherichia coli, HindIII from Haemophilus influenzae).
B. DNA Ligase (Molecular Glue)
-
Function: An enzyme that seals the “nicks” in the sugar-phosphate backbone of DNA, joining two DNA fragments together.
-
Mechanism: It catalyzes the formation of a phosphodiester bond between a 3′-hydroxyl (3′-OH) end and a 5′-phosphate (5′-P) end.
-
Critical Use: Joins the DNA fragment of interest (the “insert”) into a cut vector (plasmid) to create a recombinant DNA molecule.
C. Vectors (DNA Carriers)
A vector is a DNA molecule used to carry a foreign gene (the “insert”) into a host cell.
| Vector | Description | Insert Size | Example Uses |
|---|---|---|---|
| Plasmid | Small, circular, double-stranded DNA, naturally found in bacteria. | Up to ~10 kb | Cloning and expressing single genes in E. coli, yeast; basic DNA manipulation. |
| Lambda (λ) Phage | A virus that infects E. coli; linear DNA that can be packaged into viral heads. | 10-20 kb | Genomic DNA libraries. |
| Cosmid | Hybrid of plasmid + lambda phage cos sites; circular. | 30-45 kb | Genomic libraries for larger fragments. |
| Bacterial Artificial Chromosome (BAC) | Based on E. coli fertility (F) plasmid; circular. | 100-350 kb | Large genomic fragments for sequencing (e.g., Human Genome Project). |
| Yeast Artificial Chromosome (YAC) | Linear vector with telomeres, centromere, and ARS (autonomously replicating sequence) for replication in yeast. | 200 kb – 2 Mb | Very large genomic fragments for physical mapping and analysis of complex genomes. |
Essential Features of a Good Vector:
| Feature | Function |
|---|---|
| Origin of Replication (Ori) | Allows the vector to replicate independently inside the host cell. |
| Selectable Marker (e.g., antibiotic resistance gene – ampR, kanR, tetR) | Allows for the selection of host cells that have taken up the vector (e.g., growth on ampicillin agar kills non-transformed cells). |
| Multiple Cloning Site (MCS) / Polylinker | A short DNA segment with multiple unique restriction enzyme recognition sites, allowing for easy insertion of a foreign gene. |
| Promoter (e.g., lac, T7, CMV) | Drives the transcription of the inserted gene. Can be inducible (turned on/off). |
| Reporter Gene (optional, e.g., gfp, lacZ) | Used to verify the presence of an insert or measure gene expression levels. |
D. DNA Amplification: Polymerase Chain Reaction (PCR)
-
Function: A technique to make millions to billions of copies of a specific DNA sequence in a test tube (in vitro), without using a host cell.
-
Key Components:
-
DNA Template: The DNA fragment to be amplified.
-
Primers: Short, single-stranded synthetic DNA sequences (15-25 bp) that flank the target region. They define the start and end of the amplified segment.
-
DNA Polymerase: A heat-stable enzyme (e.g., Taq polymerase from Thermus aquaticus) that synthesizes new DNA strands.
-
Deoxynucleotide Triphosphates (dNTPs): The building blocks (A, T, G, C).
-
Buffer solution with MgCl₂ (a cofactor for polymerase).
-
-
The Three-Step Cycle (Denaturation, Annealing, Extension): Each cycle doubles the number of target DNA molecules.
E. Molecular Probes & Hybridization
-
Probe: A single-stranded DNA or RNA fragment, labeled with a detectable marker (radioactive, fluorescent, or chemical), used to detect the presence of a complementary sequence.
-
Hybridization: The process by which a single-stranded probe binds (anneals) to a complementary target DNA or RNA sequence.
-
Common Techniques:
-
Southern Blot: Detects a specific DNA sequence (e.g., confirm transgene integration).
-
Northern Blot: Detects and quantifies specific RNA transcripts (e.g., measure transgene expression).
-
Western Blot: Detects a specific protein (e.g., confirm protein production from a transgene).
-
Colony Hybridization: Screens bacterial colonies for the presence of a specific DNA sequence.
-
FISH (Fluorescent In Situ Hybridization): Visualizes the location of a specific DNA sequence on chromosomes.
-
F. Gel Electrophoresis
-
Function: A technique that separates DNA, RNA, or protein fragments by size and charge.
-
Principle: DNA/RNA is negatively charged; when placed in an electric field in an agarose or polyacrylamide gel matrix, the fragments migrate toward the positive electrode (anode). Smaller molecules move faster through the gel pores. The resulting pattern of bands is visualized with a DNA-binding dye (e.g., ethidium bromide, SYBR Safe) under UV/blue light.
3. DNA Sequencing
Determining the exact order of nucleotides in a DNA molecule is critical for identifying genes, confirming cloning, and diagnosing mutations.
-
Sanger (Chain-termination) Sequencing (1st Generation):
-
Uses modified nucleotides (dideoxynucleotide triphosphates – ddNTPs) that lack a 3′-OH group. When incorporated by DNA polymerase, they terminate DNA strand elongation.
-
A reaction with a single primer and all four dNTPs, plus one labeled ddNTP, produces a nested set of terminated fragments. These are separated by high-resolution gel electrophoresis, and the sequence is read directly from the gel autoradiogram or fluorescence trace.
-
-
Next-Generation Sequencing (NGS, High-Throughput Sequencing):
-
Massively parallel approaches that can sequence millions of fragments simultaneously at a low cost.
-
Examples: Illumina (sequencing by synthesis), Ion Torrent, PacBio (SMRT sequencing), Oxford Nanopore.
-
Applications: Whole-genome sequencing, transcriptome analysis (RNA-seq), metagenomics, epigenetic profiling.
-
How DNA Sequencing (Sanger) Works
-
Denature double-stranded DNA to single strands.
-
Anneal a specific primer to the template strand.
-
DNA polymerase extends the primer by adding complementary dNTPs.
-
Four separate reaction tubes are set up, each containing all four dNTPs and a small amount of a specific ddNTP (ddATP, ddTTP, ddCTP, or ddGTP). Whenever a ddNTP is incorporated, chain extension stops.
-
The resulting fragments are separated by electrophoresis, and the sequence is read from the gel or fluorescence chromatogram.
4. Gene Cloning: The Process of Making Recombinant DNA
The goal of gene cloning is to produce many copies of a specific gene or DNA segment. This is most commonly done by inserting the fragment into a plasmid vector and growing it in bacteria.
| Step | Description |
|---|---|
| 1. Gene Isolation | The target gene is obtained. Methods include: a) PCR amplification: Amplify from genomic DNA, cDNA, or a plasmid. b) Restriction digest: Cut it out of a larger DNA fragment. c) Artificial gene synthesis: Chemically synthesize the gene in a lab. |
| 2. Vector Preparation | A plasmid is cut with the same restriction enzyme(s) used to isolate the gene. This creates complementary sticky ends. |
| 3. Ligation | The gene fragment (insert) and the cut plasmid (vector) are mixed with DNA ligase. The ligase seals the DNA backbone, creating a recombinant DNA molecule. |
| 4. Transformation (Introduction into Host) | The recombinant DNA is introduced into host cells (typically E. coli). Common methods: a) Chemical transformation (Heat shock): Cells are treated with CaCl₂ to make them permeable to DNA. b) Electroporation: A brief electrical pulse creates temporary pores in the cell membrane. |
| 5. Screening & Selection | Only cells that have taken up a plasmid are selected, usually by antibiotic resistance (e.g., growth on ampicillin). Blue/white screening (α-complementation): The vector contains a fragment of the lacZ (β-galactosidase) gene. Inserts disrupt this gene, causing colonies with an insert to remain white on X-gal media. Colonies without an insert are blue. |
| 6. Harvesting & Purification | Selected colonies are grown in large liquid cultures. The cloned DNA (plasmid) is then extracted and purified from the bacteria using a miniprep or maxiprep kit. |
5. Gene Expression
Simply having a gene is not enough; it must be transcribed and translated. Gene expression systems are designed to produce large quantities of a specific protein.
Common Gene Expression Systems
| System | Host | Strengths | Weaknesses | Applications |
|---|---|---|---|---|
| Prokaryotic | E. coli (common) | High yield, fast growth (20 min doubling), cheap, simple. | No post-translational modifications (PTMs, e.g., glycosylation, phosphorylation); may form insoluble inclusion bodies; cannot process introns from eukaryotic genes. | Production of simple proteins (insulin, growth factors), enzymes. |
| Yeast | S. cerevisiae, P. pastoris | Eukaryotic (some PTMs); high yield (secreted); fast growth; GRAS organism. | May add inappropriate (high mannose) glycosylation. | Vaccines (Hepatitis B), hormones, industrial enzymes. |
| Insect | Baculovirus + insect cells (Sf9) | High-level expression of complex eukaryotic proteins; better PTMs than yeast; large proteins. | More expensive and complex than bacterial; slower growth. | Recombinant proteins for research (e.g., G-protein coupled receptors). |
| Mammalian | CHO (Chinese Hamster Ovary), HEK293 | Most authentic PTMs (human-like glycosylation); correct protein folding. | Very expensive; slow growth; low yields; viral contamination risk. | Therapeutic proteins (monoclonal antibodies, EPO, blood clotting factors). |
6. Gene Editing (Precision Genome Engineering)
Unlike traditional cloning (which inserts DNA randomly), gene editing allows for precise changes at a specific location in the genome.
Key Gene Editing Technologies
| Technology | Mechanism | Advantage | Disadvantage | Status |
|---|---|---|---|---|
| ZFNs (Zinc Finger Nucleases) | Engineered proteins with a DNA-binding domain (Zinc Finger) fused to a nuclease (FokI). | First programmable nucleases. | Complex and expensive to engineer for each new target. | Historical (replaced by CRISPR). |
| TALENs (Transcription Activator-Like Effector Nucleases) | Similar to ZFNs; DNA-binding domain from Xanthomonas bacteria (TALE). | Easier to engineer than ZFNs; high specificity. | Large, repetitive DNA sequence; expensive. | Historical (replaced by CRISPR). |
| CRISPR/Cas9 (Most common and advanced) | RNA-guided nuclease: a single guide RNA (sgRNA) directs the Cas9 protein to its DNA target via complementary base pairing. | Very easy, cheap, fast, and scalable to new targets. Multiplexing (edit many genes at once). | Potential for off-target editing (editing wrong gene). | Current standard; continuously being improved (base editing, prime editing). |
The CRISPR/Cas9 System: A Detailed Look
The CRISPR/Cas9 system is an adaptive immune system in bacteria that has been repurposed as a revolutionary gene-editing tool.
-
Components:
-
Cas9 Protein: A nuclease that creates a double-strand break (DSB) in DNA.
-
Single Guide RNA (sgRNA): A synthetic RNA molecule (~100 nt) that combines two natural RNAs (crRNA and tracrRNA). It has a 20-nucleotide sequence at its 5′ end that is complementary to the target DNA.
-
-
Mechanism:
-
The sgRNA binds to the target DNA sequence (which must be adjacent to a short 3′ sequence called the Protospacer Adjacent Motif (PAM), e.g., NGG for SpCas9).
-
The Cas9 protein cuts both strands of DNA, creating a DSB.
-
-
DNA Repair Pathways (The Editing Part):
-
Non-Homologous End Joining (NHEJ): Error-prone repair. Causes small insertions or deletions (indels). These often disrupt (knock out) the target gene.
-
Homology-Directed Repair (HDR): High-fidelity repair, but requires a provided “donor template.” Used to knock in a new gene or make specific point mutations.
-
Second-Generation Editing Tools (Even More Precise)
| Technology | Mechanism | Capability |
|---|---|---|
| Base Editing | Fuses a catalytically impaired Cas9 (nickase) to a deaminase enzyme. Converts one base pair directly to another without creating a DSB. | C→T (or G→A) by cytosine base editor (CBE); A→G (or T→C) by adenine base editor (ABE). |
| Prime Editing | Fuses Cas9 nickase to a reverse transcriptase (RT) with a “prime editing guide RNA” (pegRNA). Uses the pegRNA as a template to copy new sequence information into the genome. | Can make all 12 possible single-base substitutions, small insertions, and small deletions (up to ~40 bp). “Search-and-replace” for DNA. |
7. Transgenesis: Creating Genetically Modified Organisms (GMOs)
Transgenesis is the process of introducing a foreign gene(s) into the genome of an organism, which then becomes a heritable trait.
A. Creating Transgenic Plants
| Method | How It Works | Advantages | Disadvantages | Common Use |
|---|---|---|---|---|
| Agrobacterium tumefaciens | Uses a natural plant pathogen. The bacterium’s Ti plasmid has a “T-DNA” region that is transferred to plant cells. The foreign gene of interest is inserted between the T-DNA borders. | High efficiency for dicots; stable, low-copy integration. | Lower efficiency for monocots (like cereals). | Soybean, tomato, cotton, canola, poplar. |
| Particle Biolistic (Gene Gun) | High-velocity gold or tungsten microparticles are coated with DNA and shot into plant cells. | Works on any plant species (including monocots, chloroplasts). | More complex integration (multiple copies); higher equipment cost. | Corn, wheat, rice, soybean, chloroplast engineering. |
| Protoplast Transformation | Plant cell wall is removed (protoplast). DNA is introduced via PEG treatment or electroporation. | Direct gene transfer. | Regenerating whole plants from protoplasts is difficult for many species. | Research, some crops. |
Key application example for agriculture:
-
Bt Crops: Cotton, maize, and brinjal (eggplant) have been engineered to express cry genes from the bacterium Bacillus thuringiensis. The plant produces a protein that is toxic to specific insect pests (Lepidoptera, Coleoptera), reducing the need for chemical insecticide sprays.
-
Herbicide-Resistant Crops (e.g., Roundup Ready): Plants are engineered with a cp4 epsps gene (from Agrobacterium) producing a form of the EPSPS enzyme that is not inhibited by the herbicide glyphosate. This allows farmers to spray glyphosate to kill weeds without harming the crop.
B. Creating Transgenic Animals (for Research or Biopharming)
| Method | How It Works | Disadvantages | Common Use |
|---|---|---|---|
| Pronuclear Microinjection | Linear DNA is physically injected into the male pronucleus of a newly fertilized egg. The egg is then implanted into a surrogate mother. | Very inefficient (only ~5% of pups carry the transgene); random integration; can cause insertional mutations. | Production of many GM mice for research; generation of large animals (cows, goats) for protein production in milk. |
| CRISPR/Cas9 (Most modern method) | Cas9 mRNA and sgRNA (plus donor template for HDR) are injected into fertilized eggs. | Requires knowledge of target sequence; potential off-target effects. | Mouse and rat models: Highly efficient and fast (4-6 weeks). Can create knockouts, knock-ins, and point mutations. |
| Embryonic Stem (ES) Cell Method (Primarily for mice) | The foreign gene is introduced into cultured mouse ES cells. Cells with the correct integration are selected and injected into a blastocyst, which is implanted into a pseudopregnant female. | Only works in mice (and a few other species). Complex and time-consuming (months). | Classic method for creating knockout mice (targeted gene disruption). |
8. Applications of Genetic Engineering
| Field | Application | Example |
|---|---|---|
| Medicine | Recombinant protein production (largest impact). | Human insulin (Humulin, 1982 – first approved GM product), human growth hormone (hGH), erythropoietin (EPO), tissue plasminogen activator (tPA), clotting factors, monoclonal antibodies (e.g., Herceptin, Rituxan). |
| Gene therapy (experimental). | FDA-approved for some diseases: Luxturna (RPE65 mutation for inherited blindness), Zolgensma (SMN1 gene for spinal muscular atrophy), CAR-T cells (engineered T-cells for cancer). | |
| DNA vaccines. | Hepatitis B vaccine (produced in yeast). | |
| Agriculture | Insect-resistant crops. | Bt corn, Bt cotton, Bt brinjal. |
| Herbicide-tolerant crops. | Roundup Ready® soybeans, corn, canola, sugar beet, alfalfa. | |
| Virus-resistant plants. | Rainbow papaya (resistant to Papaya Ringspot Virus – PRSV), GM squash (resistant to watermelon mosaic virus and zucchini yellow mosaic virus). | |
| Improved nutrition (Biofortification). | Golden Rice (engineered to produce β-carotene, a Vitamin A precursor). | |
| Delayed ripening (longer shelf life). | Flavr Savr tomato (1994, now discontinued; uses antisense RNA to inhibit polygalacturonase, an enzyme that softens the fruit). | |
| Environment | Bioremediation. | Genetically engineered bacteria (e.g., Pseudomonas strains) designed to degrade oil spills, heavy metals, and pesticides. |
| Research | Transgenic animal models. | Oncomouse (carries a cancer gene), Alzheimer’s mouse models (expressing human APP, presenilin genes). |
| Gene function studies. | Knockout mice (a specific gene is disrupted to study its function). | |
| Industry | Production of industrial enzymes. | Chymosin (used to coagulate milk in cheese production, replacing calf rennet), proteases, lipases, amylases in detergents, food processing, and biofuels. |
| Biofuels. | Engineering microorganisms to improve ethanol production from cellulosic biomass. |
9. Regulation and Ethics
-
Regulatory Oversight: Varies by country. In the US, GM plants are regulated by the USDA (ensures plant health), EPA (regulates pesticides), and FDA (ensures food and feed safety).
-
Major Concerns & Counterarguments:
| Concern | Proponent’s View / Counterargument |
|---|---|
| Safety for Human Consumption | GM crops are the most extensively tested food products in history. Major scientific bodies (WHO, NAS, FAO, EFSA, Royal Society) have repeatedly concluded that approved GM foods are safe to eat. No documented cases of harm from GM foods. |
| Environmental Impact | Bt crops have drastically reduced chemical pesticide use, benefiting beneficial insects and farmworkers. Gene flow to wild relatives is possible but is manageable via isolation distances and sterile hybrids (e.g., terminator technology – not commercially used). |
| Corporate Control & Seed Patents | Patents reward innovation and investment in R&D. Saved seed is not always beneficial (modern hybrid seeds do not breed true). Many conventional seeds are also patented. |
| Ethical Concerns | Respects consumer choice: 70+ countries require GM labeling (including all of Europe, Japan, China, Brazil). Allows individuals to make informed decisions. |
10. Key Terms & Definitions
| Term | Definition |
|---|---|
| Recombinant DNA (rDNA) | A DNA molecule created in the lab by combining DNA sequences from two or more different sources. |
| Transgenic (Genetically Modified/GM) | An organism that has had a foreign gene(s) artificially inserted into its genome. |
| Host | The organism (e.g., E. coli cell, yeast, plant, mouse) that receives and replicates the recombinant DNA. |
| Clone | 1) An exact genetic copy (e.g., a population of genetically identical cells or organisms). 2) A recombinant DNA molecule (e.g., a plasmid containing a human gene). |
| Genomic Library | A collection of clones containing all the genomic DNA fragments (coding and non-coding) of an organism. |
| cDNA Library | A collection of clones containing only complementary DNA (cDNA), which is synthesized from an organism’s expressed mRNA. Represents only the protein-coding genes. |
| Knockout (KO) | An organism (usually a mouse) in which a specific gene has been completely disrupted or “knocked out” (often by inserting a selectable marker). Used to study the function of that gene. |
| Knock-in (KI) | An organism in which a specific gene has been replaced with an altered version (e.g., humanized gene) or a reporter gene (e.g., GFP) has been inserted into the locus. |
| Gene Drive | A genetic system that biases the inheritance of a particular gene to increase its prevalence in a population. Potential use: spreading genes to eliminate disease-carrying insects (e.g., malaria-resistant mosquitoes). Ethical concerns exist. |
| GMO (Genetically Modified Organism) | A broad term for an organism whose genetic material has been altered using genetic engineering techniques. |
11. Exam Tips & Mnemonics
-
The Tools (Restriction Enzymes, Ligase, PCR): “Restriction Cuts, Ligase Links, PCR Piles it on.” (Restriction = Cuts, Ligase = Links, PCR = Piles/Makes copies).
-
Plasmid Vector Features: “Select, Replicate, Clone, Express” – Selectable marker, Replication origin (Ori), Cloning site (MCS), Expression elements (Promoter, terminator).
-
Sanger Sequencing Steps: “Denature, Anneal, Extend, Separate” – Denaturation, Annealing, Extension, Separation (electrophoresis).
-
CRISPR Components (Cas9, sgRNA, PAM): “Cas9 Cuts, SgRNA Steers, PAM Provides a Passcode.”
-
DNA Repair Pathways: “NHEJ: Not-so-Homologous (error-prone), good for Just Joining; HDR: Homologous, needs Donor Report (high fidelity).”
-
Host Expression Systems: “Prokaryotes (E. coli) are Primitive (no PTM), Yeast are Young adults (some PTM), Mammalian are Mature (correct PTM).”
Common Pitfalls
| Mistake | Correction |
|---|---|
| Confusing cDNA and genomic DNA libraries | Genomic library = from total DNA (coding + non-coding). cDNA library = from reverse-transcribed mRNA (only protein-coding exons, no introns). |
| Forgetting that sticky ends are required for efficient ligation | Ligation works with blunt ends, but with much lower efficiency. |
| Overlooking the importance of selectable markers (antibiotic resistance) | Without a selectable marker, it’s nearly impossible to find the rare cells that took up the plasmid. |
| Believing PCR requires restriction enzymes | PCR only needs primers, DNA polymerase, and dNTPs; no restriction enzymes required. |
| Thinking CRISPR edits RNA | CRISPR/Cas9 edits DNA. Some variants (Cas13) target RNA, but standard CRISPR/Cas9 is DNA editing. |
| Assuming all GMOs are transgenic plants | GMOs include animals (mice, goats, salmon), microbes (E. coli for insulin), and even humans (gene therapy). |
Immunology – Comprehensive Study Notes
These notes provide a detailed analysis of immunology, covering the innate and adaptive immune systems, antigens and antibodies, immune cells and organs, the major histocompatibility complex (MHC), immune responses, immunological disorders, and applied immunology. Designed for undergraduate and graduate students in biology, medicine, and health sciences.
Part A: Foundations of the Immune System
Unit 1: Introduction to Immunology
1.1 Definition and Scope
Immunology is the study of the immune system – the body’s defense against infectious agents (bacteria, viruses, fungi, parasites) and other foreign substances, as well as its role in recognizing and eliminating abnormal cells (cancer). It also encompasses immune dysfunction (allergies, autoimmune diseases, immunodeficiencies).
1.2 Historical Milestones
| Year | Discovery | Significance |
|---|---|---|
| 1798 | Edward Jenner – smallpox vaccine (cowpox). | First vaccine; foundation of vaccinology. |
| 1880s | Louis Pasteur – attenuated vaccines (cholera, anthrax, rabies). | Germ theory; artificial attenuation. |
| 1890 | Emil von Behring & Shibasaburo Kitasato – antitoxins (diphtheria, tetanus). | Humoral immunity; serum therapy. |
| 1905 | Elie Metchnikoff – phagocytosis (cellular immunity). | Discovery of macrophages, neutrophils. |
| 1940s | Karl Landsteiner – ABO blood groups. | Transplantation immunology. |
| 1950s | Peter Medawar – acquired immunological tolerance. | Clonal selection theory. |
| 1959 | Rodney Porter, Gerald Edelman – antibody structure. | Immunoglobulin classes. |
| 1975 | Georges Köhler & César Milstein – monoclonal antibodies (hybridoma technology). | Revolutionized diagnostics, therapeutics. |
| 1980s | Discovery of HIV (human immunodeficiency virus). | AIDS epidemic. |
| 1990s | Dendritic cells (Ralph Steinman). | Key link between innate and adaptive immunity. |
| 2010s | Cancer immunotherapy (checkpoint inhibitors – CTLA‑4, PD‑1, PD‑L1), CAR‑T cells. | Nobel Prize 2018 (James Allison, Tasuku Honjo). |
Unit 2: Innate Immunity (Non‑specific)
2.1 Characteristics
| Feature | Innate Immunity | Adaptive Immunity |
|---|---|---|
| Specificity | Broad (recognizes PAMPs – pathogen‑associated molecular patterns). | Highly specific (antigen‑specific). |
| Speed | Immediate (minutes to hours). | Slower (days; requires clonal expansion). |
| Memory | No (same response each time). | Yes (immunological memory). |
| Components | Physical barriers (skin, mucous membranes), phagocytes (neutrophils, macrophages), NK cells, complement, cytokines. | Lymphocytes (B cells, T cells), antibodies. |
2.2 Physical and Chemical Barriers
| Barrier | Mechanism |
|---|---|
| Skin | Keratinized epithelium (physical barrier); low pH (sweat – lactic acid); antimicrobial peptides (defensins, cathelicidins). |
| Mucous membranes (respiratory, gastrointestinal, urogenital). | Mucus traps pathogens; cilia sweep out; lysozyme (tears, saliva, nasal secretions) breaks bacterial cell walls; gastric acid (pH 1‑2); lactoferrin (binds iron, inhibits bacterial growth). |
2.3 Cellular Components of Innate Immunity
| Cell Type | Function | Tissue Distribution |
|---|---|---|
| Neutrophils | Phagocytosis (first responder). | Blood (most abundant leukocyte). |
| Macrophages (from monocytes). | Phagocytosis; antigen presentation; cytokine production; tissue repair. | Tissues (Kupffer cells – liver; microglia – CNS; alveolar macrophages – lung; histiocytes – connective tissue). |
| Dendritic Cells (DCs) | Antigen presentation (link innate → adaptive). Primary activators of naïve T cells. | Skin (Langerhans cells), lymph nodes, spleen, mucosal tissues. |
| Natural Killer (NK) Cells | Kill virus‑infected cells and tumor cells (without prior sensitization). Respond to “missing self” (lack of MHC class I). | Blood, spleen, liver. |
| Eosinophils | Defense against helminths (parasitic worms); involved in allergic reactions. | Blood (low numbers), mucosal tissues. |
| Basophils / Mast Cells | Release histamine, heparin, cytokines (allergic reactions, defense against parasites). | Basophils: blood; Mast cells: tissues (skin, mucosa). |
2.4 Pattern Recognition Receptors (PRRs) and PAMPs
-
PAMPs (Pathogen‑Associated Molecular Patterns) : Conserved molecules on pathogens not found on host cells.
-
LPS (lipopolysaccharide) – Gram‑negative bacteria.
-
Lipoteichoic acid – Gram‑positive bacteria.
-
Peptidoglycan – bacteria.
-
Flagellin – bacterial flagella.
-
dsRNA – viral replication intermediate (recognized by TLR3).
-
ssRNA – some viruses (recognized by TLR7/8).
-
Unmethylated CpG DNA – bacteria, viruses (recognized by TLR9).
-
-
PRRs (Pattern Recognition Receptors) :
-
Toll‑like receptors (TLRs) : Transmembrane (endosomal or cell surface). Recognize PAMPs. Activate NF‑κB and IRF signaling pathways → cytokine production.
-
NOD‑like receptors (NLRs) : Cytoplasmic. Recognize bacterial peptidoglycan fragments. Form inflammasomes (activate caspase‑1 → IL‑1β, IL‑18).
-
RIG‑I‑like receptors (RLRs) : Cytoplasmic. Recognize viral RNA.
-
C‑type lectin receptors (CLRs) : Recognize fungal cell wall components (mannose, β‑glucan).
-
2.5 Phagocytosis
Steps:
-
Chemotaxis → 2. Recognition and attachment (opsonins – complement C3b, antibodies IgG) → 3. Engulfment (pseudopods) → 4. Phagosome formation → 5. Phagosome‑lysosome fusion → 6. Killing and degradation (acidification, reactive oxygen species – ROS, reactive nitrogen species – RNS, antimicrobial peptides, enzymes) → 7. Exocytosis of debris (and antigen presentation via MHC class II).
2.6 Complement System
-
Function: Opsonization (C3b), chemotaxis (C5a), cell lysis (membrane attack complex – MAC – C5b‑C9), inflammation (C3a, C5a anaphylatoxins).
-
Activation pathways:
-
Classical pathway: Activated by antibody‑antigen complexes (IgG, IgM). C1q, C1r, C1s → C4, C2 → C3 convertase (C4b2a).
-
Lectin pathway: Activated by mannose‑binding lectin (MBL) binding to mannose residues on pathogens. MBL‑associated serine proteases (MASP‑1, MASP‑2) → similar to classical.
-
Alternative pathway: Activated directly on pathogen surfaces (spontaneous hydrolysis of C3; factor B, factor D). C3 convertase (C3bBb).
-
-
Regulation: Decay‑accelerating factor (DAF, CD55), CD59 (protects host cells from MAC), Factor H, Factor I.
Unit 3: Adaptive Immunity
3.1 Characteristics
-
Specificity: Recognizes specific antigens (epitopes).
-
Diversity: Millions of antigen receptors (BCR on B cells, TCR on T cells) generated by somatic recombination (V(D)J recombination).
-
Memory: Faster, stronger response upon second exposure (immunological memory).
-
Self‑tolerance: Discrimination between self and non‑self (central and peripheral tolerance).
3.2 Lymphocytes
| Lymphocyte | Origin | Maturation Site | Receptor | Function |
|---|---|---|---|---|
| B cells | Bone marrow | Bone marrow (mammals). | B cell receptor (BCR) – membrane‑bound Ig (IgM, IgD). | Humoral immunity: differentiate into plasma cells (secrete antibodies). |
| T cells | Bone marrow | Thymus. | T cell receptor (TCR) – αβ (most) or γδ. | Cellular immunity: help B cells (CD4+ T helper cells), kill infected cells (CD8+ cytotoxic T cells). |
3.3 Antigens and Epitopes
-
Antigen: Any molecule (usually protein, polysaccharide) that can be recognized by the immune system.
-
Immunogen: Antigen that can elicit an adaptive immune response (most antigens are immunogens; some small molecules – haptens – require carrier protein).
-
Epitope (antigenic determinant) : Specific portion of antigen recognized by antibody or TCR (linear epitope – continuous amino acid sequence; conformational epitope – 3D structure, discontinuous residues).
3.4 Antibodies (Immunoglobulins – Ig)
Structure:
-
4 polypeptide chains: 2 heavy chains (H) and 2 light chains (L) (κ or λ).
-
Disulfide bonds between H‑H and H‑L.
-
Fab (antigen‑binding fragment) : Variable regions (VH + VL) – antigen binding site. Two Fab per antibody.
-
Fc (crystallizable fragment) : Constant regions of heavy chains (CH2, CH3) – binds to Fc receptors on immune cells, complement C1q.
Antibody Classes (Isotypes) :
| Isotype | Heavy Chain | Structure | Location | Function |
|---|---|---|---|---|
| IgG | γ | Monomer. | Blood, extracellular fluid (crosses placenta). | Opsonization, ADCC, complement activation (classical), neonatal immunity (via FcRn). |
| IgA | α | Monomer (serum) or dimer (secretory). | Mucosal surfaces (tears, saliva, breast milk, respiratory, GI, urogenital). | Neutralization, prevents pathogen adherence to mucosa. |
| IgM | μ | Pentamer (with J chain). | Blood (mostly). | Primary response (first antibody produced). Efficient complement activation. |
| IgE | ε | Monomer. | Bound to mast cells and basophils via FcεRI. | Defense against helminths; allergic reactions. |
| IgD | δ | Monomer. | B cell surface (co‑expressed with IgM). | B cell activation (function not fully understood). |
3.5 B Cell Development and Activation
-
Development: Bone marrow.
-
Pro‑B cell: D‑J rearrangement (heavy chain).
-
Pre‑B cell: V‑DJ rearrangement (heavy chain). Express pre‑BCR (μ heavy chain + surrogate light chain – VpreB, λ5).
-
Immature B cell: Light chain rearrangement (V‑J). Express IgM on surface.
-
Mature (naïve) B cell: Co‑express IgM and IgD. Migrate to secondary lymphoid organs (lymph nodes, spleen).
-
-
Negative selection: Eliminates self‑reactive immature B cells (clonal deletion) or induces receptor editing (re‑arranges light chain).
-
Activation (T‑dependent antigens – proteins):
-
BCR binds antigen (internalizes, processes, presents peptide on MHC class II).
-
Helper T cell (CD4+) recognizes same peptide via TCR; CD40L (on T cell) binds CD40 (on B cell); cytokines (IL‑4, IL‑5, IL‑21) promote B cell proliferation, class switching, affinity maturation in germinal centers.
-
Class switching: Changes constant region (μ → γ, α, ε) mediated by AID (activation‑induced cytidine deaminase). Different isotype (IgG, IgA, IgE) with same antigen specificity.
-
Affinity maturation: Somatic hypermutation (SHM) in variable region genes; B cells with higher affinity selected (by limiting antigen in germinal centers).
-
Differentiation: Plasma cells (secrete antibodies) and memory B cells.
-
-
Activation (T‑independent antigens – polysaccharides, lipids):
-
B cell activated without T cell help (repeated epitopes cross‑link BCR). Produces IgM (no class switching, no affinity maturation, no memory). Examples: bacterial capsular polysaccharides, lipopolysaccharide (LPS).
-
3.6 T Cell Development and Activation
-
Development: Bone marrow → thymus.
-
Double‑negative (DN) stage: CD4⁻ CD8⁻. Rearrangement of β chain (TCRβ).
-
Double‑positive (DP) stage: CD4⁺ CD8⁺. Rearrangement of α chain (TCRα).
-
Positive selection: DP cells with TCR that can recognize self‑MHC (MHC class I or class II) survive (bind with low affinity). If no binding → apoptosis (death by neglect).
-
Lineage commitment: TCR + MHC class I → CD8⁺; TCR + MHC class II → CD4⁺.
-
Negative selection: Cells with high affinity for self‑peptide + self‑MHC undergo apoptosis (clonal deletion). Central tolerance.
-
-
Activation (CD4+ T helper cells):
-
TCR recognizes peptide antigen presented by MHC class II on antigen‑presenting cell (APC – dendritic cell, macrophage, B cell).
-
Co‑stimulation: CD28 (T cell) binds CD80/CD86 (APC). Without co‑stimulation → anergy (unresponsiveness).
-
Cytokines from APC and T cells drive differentiation into subsets:
-
Th1 (IL‑12, IFN‑γ): Activates macrophages, enhances killing of intracellular bacteria (e.g., Mycobacterium tuberculosis). Key cytokine: IFN‑γ.
-
Th2 (IL‑4): Promotes eosinophil and mast cell responses (helminths). Key cytokines: IL‑4, IL‑5, IL‑13.
-
Th17 (TGF‑β + IL‑6, IL‑23): Recruits neutrophils; defense against extracellular bacteria and fungi. Key cytokine: IL‑17.
-
Treg (regulatory T cells) : Suppresses immune responses; prevents autoimmunity. Key transcription factor: FoxP3. Cytokines: IL‑10, TGF‑β.
-
Tfh (follicular helper) : Helps B cells in germinal centers. Key cytokine: IL‑21.
-
-
-
Activation (CD8+ cytotoxic T cells):
-
TCR recognizes peptide on MHC class I (presented by any nucleated cell). Activated CD8+ T cells kill infected cells via:
-
Perforin/granzyme pathway: Perforin forms pores; granzymes enter, activate caspases → apoptosis.
-
Fas/FasL pathway: FasL (CD95L) on T cell binds Fas (CD95) on target cell → caspase activation → apoptosis.
-
-
Part B: Major Histocompatibility Complex (MHC)
Unit 4: MHC and Antigen Presentation
4.1 MHC Classes
| Feature | MHC Class I | MHC Class II |
|---|---|---|
| Chains | α chain (heavy) + β2‑microglobulin (β2m). | α and β chains (both transmembrane). |
| Expression | All nucleated cells (and platelets). | Professional APCs (dendritic cells, macrophages, B cells); also some epithelial cells (inducible). |
| Peptide source | Endogenous (cytosolic) – viral proteins, tumor antigens. | Exogenous (endocytosed) – extracellular pathogens, internalized antigens. |
| Peptide length | 8‑10 amino acids. | 13‑25 amino acids. |
| Loading location | Endoplasmic reticulum (ER). TAP (transporter associated with antigen processing) imports peptides into ER. | Endosomes / lysosomes. CLIP (class II‑associated invariant chain peptide) blocks groove until replaced by antigenic peptide. |
| CD8+ T cell (cytotoxic). | CD8 binds α3 domain. | — |
| CD4+ T cell (helper). | — | CD4 binds β2 domain. |
4.2 Antigen Processing and Presentation Pathways
-
MHC Class I pathway (cross‑presentation by dendritic cells also allows exogenous antigens to enter MHC I pathway – important for anti‑viral and anti‑tumor immunity).
-
MHC Class II pathway: Invariant chain (Ii) blocks peptide‑binding groove in ER, directs transport to endosomes. Cathepsin cleaves Ii, leaving CLIP fragment. HLA‑DM (in humans) removes CLIP, facilitates binding of antigenic peptide.
Unit 5: Immune Effector Mechanisms
5.1 Humoral Immunity (Antibody‑Mediated)
| Mechanism | Description |
|---|---|
| Neutralization | Antibody binds to pathogen or toxin, blocks attachment to host cells. |
| Opsonization | Antibody (IgG) coats pathogen; Fc region binds Fcγ receptors on phagocytes → enhanced phagocytosis. |
| Complement activation | Classical pathway (IgG, IgM) → C3b deposition (opsonization) and MAC formation (lysis). |
| ADCC (Antibody‑Dependent Cellular Cytotoxicity) | IgG bound to target cell; NK cells bind via FcγRIII (CD16) → release perforin/granzymes → kill target cell. |
5.2 Cell‑Mediated Immunity
-
CD8+ cytotoxic T cells kill virus‑infected cells and tumor cells.
-
Th1 cells activate macrophages (enhance killing of intracellular bacteria).
-
Th2 cells activate eosinophils (helminths) and mast cells.
-
Th17 cells recruit neutrophils (extracellular bacteria, fungi).
-
Treg cells suppress immune responses (prevents autoimmunity, limits chronic inflammation).
Unit 6: Immunological Disorders
6.1 Hypersensitivity Reactions (Gell and Coombs Classification)
| Type | Name | Mechanism | Examples |
|---|---|---|---|
| Type I | Immediate (anaphylactic). | IgE bound to mast cells; allergen cross‑links IgE → mast cell degranulation (histamine, leukotrienes, prostaglandins). | Allergic rhinitis (hay fever), asthma, anaphylaxis, food allergies. |
| Type II | Cytotoxic. | Antibody (IgG, IgM) binds to cell surface antigens → complement activation, ADCC, opsonization. | Autoimmune hemolytic anemia, Goodpasture syndrome, Graves’ disease (TSH receptor antibody). |
| Type III | Immune complex. | Soluble antigen‑antibody complexes deposit in tissues → complement activation → inflammation (vasculitis, glomerulonephritis). | Serum sickness, SLE (systemic lupus erythematosus), post‑streptococcal glomerulonephritis. |
| Type IV | Delayed‑type (cell‑mediated). | T cell‑mediated (no antibody). CD4+ T cells secrete cytokines → macrophage activation, inflammation (48‑72 hours). | Tuberculin skin test (PPD), contact dermatitis (poison ivy, nickel), Type 1 diabetes (insulitis). |
6.2 Autoimmune Diseases
| Disease | Autoantigen | Mechanism | Target organ |
|---|---|---|---|
| Rheumatoid arthritis (RA). | Rheumatoid factor (IgG Fc), citrullinated proteins (anti‑CCP). | Immune complexes (type III); Th17 cells. | Joints (synovium). |
| Systemic lupus erythematosus (SLE). | dsDNA, histones, Sm, Ro (SSA), La (SSB), phospholipids. | Immune complexes (type III) → vasculitis, glomerulonephritis. | Multiple organs (skin, kidneys, joints, serosa, CNS). |
| Type 1 diabetes (T1D). | Insulin, GAD65 (glutamic acid decarboxylase), IA‑2, ZnT8. | T cell‑mediated (type IV) destruction of pancreatic β‑cells. | Pancreas (islets of Langerhans). |
| Multiple sclerosis (MS). | Myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG). | T cell‑mediated (type IV) demyelination. | CNS (brain, spinal cord, optic nerves). |
| Hashimoto’s thyroiditis. | Thyroglobulin, thyroid peroxidase (TPO). | Autoantibodies (type II) + T cell infiltration. | Thyroid. |
| Graves’ disease. | TSH receptor (stimulating antibody). | Type II (autoantibody activates TSH receptor). | Thyroid. |
| Myasthenia gravis. | Acetylcholine receptor (AChR). | Type II (antibody blocks AChR). | Neuromuscular junction. |
6.3 Immunodeficiencies
| Type | Example | Defect | Clinical Features |
|---|---|---|---|
| Primary (genetic) | Severe combined immunodeficiency (SCID). | Defect in T cell development (e.g., adenosine deaminase – ADA deficiency; cytokine receptor common γ chain – X‑linked SCID). | Absent T cells; recurrent infections (viral, fungal, opportunistic). |
| X‑linked agammaglobulinemia (Bruton). | BTK mutation (Bruton tyrosine kinase) – failure of B cell maturation. | Low/absent antibodies; recurrent bacterial infections (pyogenic). | |
| DiGeorge syndrome. | 22q11.2 deletion – thymic hypoplasia/aplasia. | T cell deficiency (variable), hypoparathyroidism, congenital heart defects. | |
| Secondary (acquired) | AIDS (Acquired Immunodeficiency Syndrome). | HIV infects CD4+ T cells, macrophages, dendritic cells → progressive depletion of CD4+ T cells. | Opportunistic infections (Pneumocystis jirovecii pneumonia, tuberculosis, candidiasis), malignancies (Kaposi sarcoma, non‑Hodgkin lymphoma). |
6.4 Transplantation Immunology
-
Allograft rejection:
-
Hyperacute: Minutes to hours. Pre‑existing antibodies against donor HLA (e.g., multiparous women, prior transplant).
-
Acute: Days to months. T cell‑mediated (CD8+ cytotoxic T cells, CD4+ helper T cells) or antibody‑mediated (donor‑specific antibodies).
-
Chronic: Months to years. Graft vascular disease (fibrosis, intimal hyperplasia).
-
-
Graft‑versus‑host disease (GVHD) : Donor T cells in allogeneic bone marrow transplant attack recipient tissues (skin, liver, GI tract).
-
Immunosuppressive drugs: Calcineurin inhibitors (cyclosporine, tacrolimus), mTOR inhibitors (sirolimus, everolimus), antiproliferatives (mycophenolate mofetil, azathioprine), corticosteroids, biologics (anti‑CD25 – basiliximab, anti‑CD52 – alemtuzumab, anti‑thymocyte globulin).
Unit 7: Applied Immunology
7.1 Vaccines
| Type | Description | Examples |
|---|---|---|
| Live attenuated | Weakened pathogen (replicates in host). | MMR (measles, mumps, rubella), OPV (oral polio), Yellow fever, Varicella, Rotavirus. |
| Inactivated (killed) | Chemically or heat‑killed pathogen. | IPV (inactivated polio), Hepatitis A, Rabies, Influenza (injectable). |
| Subunit (recombinant protein) | Purified antigen (protein or polysaccharide). | Hepatitis B (HBsAg), HPV (L1 VLP), Acellular pertussis (aP). |
| Toxoid | Inactivated toxin. | Tetanus, Diphtheria. |
| Conjugate | Polysaccharide linked to carrier protein. | Hib, Pneumococcal (Prevnar), Meningococcal. |
| mRNA | Lipid nanoparticle (LNP)‑encapsulated mRNA encoding antigen. | COVID‑19 (Pfizer/BioNTech – Comirnaty, Moderna – Spikevax). |
| Viral vector | Engineered virus delivers antigen gene. | COVID‑19 (Johnson & Johnson – Ad26, AstraZeneca – ChAdOx1), Ebola (Ervebo). |
7.2 Monoclonal Antibodies (mAbs) in Therapy
| Target | Disease | Example (INN). |
|---|---|---|
| CD20 | B cell lymphoma, RA | Rituximab, Ofatumumab, Obinutuzumab. |
| HER2 | HER2+ breast cancer | Trastuzumab (Herceptin), Pertuzumab. |
| TNF‑α | RA, psoriasis, IBD | Adalimumab (Humira), Infliximab, Etanercept (Fc fusion). |
| PD‑1 / PD‑L1 | Cancer (immune checkpoint blockade). | Pembrolizumab (Keytruda, PD‑1), Nivolumab (Opdivo, PD‑1), Atezolizumab (Tecentriq, PD‑L1). |
| CTLA‑4 | Melanoma | Ipilimumab (Yervoy). |
| IL‑17 | Psoriasis | Secukinumab (Cosentyx), Ixekizumab. |
| IgE | Allergic asthma | Omalizumab (Xolair). |
7.3 Immunotherapy for Cancer
-
Checkpoint inhibitors: Block inhibitory receptors (CTLA‑4, PD‑1, PD‑L1) → enhance anti‑tumor T cell responses.
-
CAR‑T cells: Patient’s T cells engineered with chimeric antigen receptor (CAR) targeting tumor antigen (e.g., CD19). Approved: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel) for B cell acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL).
-
Cancer vaccines: HPV vaccine (prophylactic), therapeutic cancer vaccines (Sipuleucel‑T for prostate cancer).
Part 2: Bioinformatics – Comprehensive Study Notes
These notes provide a detailed analysis of bioinformatics, covering sequence alignment, database searching, genome assembly and annotation, transcriptomics, proteomics, structural bioinformatics, and phylogenetics. Designed for undergraduate and graduate students in bioinformatics, molecular biology, and computational biology.
Part A: Foundations of Bioinformatics
Unit 1: Introduction to Bioinformatics
1.1 Definition and Scope
Bioinformatics is an interdisciplinary field that develops and applies computational methods to analyze large‑scale biological data (genomic, transcriptomic, proteomic, metabolomic). It integrates biology, computer science, mathematics, and statistics.
Key Subdisciplines:
-
Genomics: Analysis of genome sequences (assembly, annotation, variation).
-
Transcriptomics: Analysis of RNA (gene expression, alternative splicing).
-
Proteomics: Analysis of proteins (identification, quantification, PTMs, interactions).
-
Structural bioinformatics: Prediction and analysis of 3D structures of macromolecules.
-
Phylogenetics: Evolutionary relationships (tree building).
-
Metagenomics: Analysis of environmental DNA (microbial communities).
-
Network biology: Protein‑protein interaction networks, gene regulatory networks, metabolic pathways.
1.2 Core Biological Data Types
| Data Type | Description | File Formats |
|---|---|---|
| DNA sequence | A, T, G, C (or U for RNA). | FASTA, FASTQ (with quality scores). |
| Protein sequence | 20 amino acids. | FASTA. |
| Genomic annotations | Gene locations, exons, introns, regulatory elements, repeats. | GFF (General Feature Format), GTF (Gene Transfer Format), BED. |
| Sequence alignments | Multiple sequence alignment (MSA). | Clustal, FASTA, Nexus, Phylip. |
| 3D structures | Coordinates of atoms. | PDB (Protein Data Bank). |
| Expression data | Gene expression levels (microarray, RNA‑seq). | CEL (Affymetrix), count matrix, TPM, FPKM, RPKM. |
| Variants | SNPs, indels, structural variants. | VCF (Variant Call Format). |
| Interactions | Protein‑protein, protein‑DNA, genetic. | PSI‑MITAB, SIF. |
1.3 Major Biological Databases
| Database | Content | Access |
|---|---|---|
| GenBank (NCBI). | DNA sequences (all organisms). | NCBI website, FTP. |
| RefSeq (NCBI). | Curated, non‑redundant reference sequences. | NCBI. |
| ENA (EBI). | DNA/RNA sequences. | EBI. |
| DDBJ (Japan). | DNA sequences. | DDBJ. |
| UniProt (Universal Protein Resource). | Protein sequences (Swiss‑Prot – manually curated; TrEMBL – automatically annotated). | uniprot.org. |
| PDB (Protein Data Bank). | 3D structures (X‑ray, NMR, cryo‑EM). | rcsb.org. |
| NCBI Taxonomy | Classification of organisms. | NCBI. |
| Ensembl | Genomic annotations (vertebrates). | ensembl.org. |
| UCSC Genome Browser | Genome annotations, comparative genomics. | genome.ucsc.edu. |
| KEGG | Metabolic pathways, signaling pathways. | kegg.jp. |
| Gene Ontology (GO) | Controlled vocabulary for gene function (molecular function, biological process, cellular component). | geneontology.org. |
| InterPro | Protein domains and families (integrates Pfam, SMART, PROSITE, etc.). | InterProScan (EBI). |
| STRING | Protein‑protein interaction networks. | string‑db.org. |
| BLAST (Basic Local Alignment Search Tool). | Sequence similarity searching (not a database, but a search tool). | NCBI BLAST, EBI BLAST, UniProt BLAST. |
Part B: Sequence Alignment and Database Searching
Unit 2: Pairwise Sequence Alignment
2.1 Definitions
-
Alignment: Arranging two (pairwise) or more (multiple) sequences to identify regions of similarity (due to homology – common evolutionary origin).
-
Homology: Similarity due to descent from a common ancestor (orthologs – speciation; paralogs – duplication). “Percent homology” is incorrect; sequences are either homologous or not.
2.2 Scoring Matrices
| Matrix | Description | Use |
|---|---|---|
| Identity matrix | 1 for match, 0 for mismatch (or – for mismatch). | Comparing very closely related sequences. |
| BLOSUM (Blocks Substitution Matrix). | Derived from aligned, conserved regions (blocks) in protein families. BLOSUM62 is default for BLAST. Higher BLOSUM numbers (e.g., 80) for closely related proteins; lower (e.g., 45) for distant relationships. | Protein alignments. |
| PAM (Percent Accepted Mutation). | Based on evolutionary models (PAM1 = 1 substitution per 100 residues). PAM250 more distant. | Protein alignments (historical, less common now). |
| DNA scoring (transition/transversion). | Transitions (A↔G, C↔T) more common than transversions (purine↔pyrimidine). Higher score for transitions. | DNA alignments (phylogenetics). |
2.3 Gap Penalties
-
Gap opening penalty: Penalty for starting a gap (higher).
-
Gap extension penalty: Penalty for extending a gap (lower).
-
Affine gap penalty: Total penalty = gap opening + (gap length × gap extension). More realistic than linear penalty (gap opening + gap length × same penalty).
2.4 Alignment Algorithms
| Algorithm | Description | Use | Time complexity |
|---|---|---|---|
| Needleman‑Wunsch | Dynamic programming (global alignment). | Aligns entire sequences (same length approx). | O(n²). |
| Smith‑Waterman | Dynamic programming (local alignment). | Finds best local similarity (detects conserved domains). | O(n²). |
| BLAST (heuristic). | Seed‑and‑extend. Faster than Smith‑Waterman. | Database search (finding homologs). | O(n), fast. |
Unit 3: Multiple Sequence Alignment (MSA)
3.1 Purpose
-
Identify conserved residues (functional sites).
-
Build phylogenetic trees.
-
Predict protein secondary structure.
-
Design primers.
3.2 MSA Algorithms
| Algorithm | Description | Tools |
|---|---|---|
| Progressive | Build guide tree (distance matrix), then align sequentially (most similar pair first). | Clustal Omega, MUSCLE, MAFFT, T‑Coffee. |
| Iterative | Refine initial alignment by repeatedly realigning subgroups. | MAFFT (‑i), Muscle (‑refine). |
| Consistency‑based | Uses information from all pairwise alignments (not just guide tree). | T‑Coffee. |
| Hidden Markov Models (HMMs) | Train on aligned sequences (profile HMM). | HMMER (for building HMM profiles, searching databases). |
3.3 MSA Visualization
| Tool | Features |
|---|---|
| Jalview | Coloring (conservation, charge, hydrophobicity), editing, phylogenetic tree. |
| AliView | Lightweight, fast, editing. |
| UGENE | Integrated MSA viewer. |
Unit 4: Sequence Database Searching
4.1 BLAST (Basic Local Alignment Search Tool)
Algorithm:
-
Word (seed) generation: Break query sequence into short words (k‑mers). For protein: 3‑4 amino acids; for DNA: 11‑15 bases.
-
Neighborhood generation: For each word, generate all possible words scoring above threshold (using substitution matrix).
-
Scan database: Find hits of neighborhood words in database.
-
Extension: Extend hits in both directions (ungapped extension), then gapped extension.
-
E‑value: Expectation value – number of alignments expected by chance given database size. E‑value < 0.01 typically significant (depends on query length, database size).
-
Bit score: Log‑transformed, normalized score (independent of database size). Higher bit score = better alignment.
BLAST Programs:
| Program | Query | Database | Description |
|---|---|---|---|
| blastn | DNA | DNA | Nucleotide‑nucleotide. |
| blastp | Protein | Protein | Protein‑protein. |
| blastx | DNA (translated) | Protein | DNA‑protein (all 6 reading frames). |
| tblastn | Protein | DNA (translated) | Protein‑DNA. |
| tblastx | DNA (translated) | DNA (translated) | Translated‑translated (slow). |
Web BLAST: NCBI BLAST (blast.ncbi.nlm.nih.gov), EBI BLAST (www.ebi.ac.uk/Tools/sss).
Biochemical Engineering – Complete Study Notes
📖 Course Overview
Biochemical engineering is a specialized branch of engineering that integrates principles of biology, chemistry, and engineering to design processes that utilize living organisms (or their components) for the production of valuable materials . At its core, it answers a fundamental question: How do we scale up a biological reaction that works in a flask to an industrial process producing tons of product?
This field bridges laboratory-scale discoveries (biotechnology) with industrial-scale manufacturing. Common products include antibiotics, vaccines, biofuels, and specialty food ingredients .
Part 1: Foundations of Biochemical Engineering
1.1 Definition and Scope
Biochemical Engineering is the discipline that deals with the design, construction, and operation of processes involving living organisms or biologically active molecules (like enzymes) . It focuses on the bioprocess—a series of operations that converts raw materials into a final product using biological agents.
The Three Stages of Bioprocessing:
| Stage | Name | Description | Example Unit Operations |
|---|---|---|---|
| 1 | Upstream Processing | Preparation and growth of the biological agent. | Media preparation, sterilization, inoculum development. |
| 2 | Bioreaction (Fermentation) | The core conversion where cells/enzymes transform substrates into products. | Bioreactor operation (Batch, Fed-batch, Continuous). |
| 3 | Downstream Processing | Recovery, purification, and formulation of the product . | Filtration, centrifugation, chromatography, drying. |
1.2 Core Principles of Chemical Engineering Applied to Biology
Biochemical engineering applies traditional chemical engineering laws to biological systems, but with unique constraints due to the fragility of living cells.
-
Material Balances: “What goes in must come out.” Applied to carbon, nitrogen, and oxygen in a fermenter.
-
Energy Balances: Managing the heat generated by microbial metabolism (bioreactors often require cooling).
-
Transport Phenomena: Moving oxygen from an air bubble to a cell deep in the liquid is a critical mass transfer challenge.
1.3 Types of Biocatalysts
The “factory” in biochemical engineering can be enzymes or entire cells .
| Biocatalyst | Definition | Advantages | Challenges |
|---|---|---|---|
| Enzymes (Cell-free) | Isolated proteins that catalyze specific reactions. | High specificity, no side reactions, clean product. | Expensive to purify, unstable outside cellular conditions. |
| Microbes (Bacteria/Yeast) | Whole living cells (e.g., E. coli, Yeast). | Can perform multi-step reactions, self-replicating. | Produce metabolic by-products, requires nutrients & oxygen. |
| Animal/Plant Cells | Mammalian or plant cultures. | Essential for complex proteins (antibodies), Post-translational modifications. | Slow growth, fragile, high contamination risk, expensive media. |
Part 2: Enzyme Kinetics (The “Motor” of the Process)
Enzymes are biological catalysts that lower the activation energy of reactions. They follow specific kinetic patterns distinct from chemical catalysts due to saturation effects.
2.1 The Michaelis-Menten Equation
The standard model for enzyme kinetics assumes the formation of an enzyme-substrate complex .
E+S⇌k−1k1ES→kcatE+P
The resulting rate equation is:
v=Vmax[S]Km+[S]
Explanation of Terms:
| Parameter | Meaning | Significance |
|---|---|---|
| v | Initial reaction rate | How fast product appears. |
| [S] | Substrate concentration | The “fuel” for the reaction. |
| Vmax | Maximum rate (when all enzymes are saturated with substrate). | Proportional to total enzyme concentration (E_total). |
| Km | Substrate concentration at 1/2 Vmax. | Affinity (low Km = high affinity, enzyme grabs substrate tightly). |
Graph Shape: Hyperbolic curve (v increases with [S] until plateauing at Vmax).
2.2 Enzyme Inhibition (How to Stop the Motor)
Inhibitors reduce enzyme activity. Understanding this is crucial for avoiding product inhibition or designing drugs .
Competitive Inhibition:
-
Mechanism: Inhibitor binds to the active site (competes with S).
-
Effect on Kinetics: Vmax unchanged (can be overcome by adding more S), Km increases (apparent affinity drops).
Non-Competitive Inhibition:
-
Mechanism: Inhibitor binds to allosteric site (changes shape of enzyme).
-
Effect on Kinetics: Vmax decreases (cannot be overcome), Km unchanged.
2.3 Immobilized Enzymes
In industrial processes, enzymes are often attached to solid supports (beads, membranes) .
Advantages of Immobilization:
-
Reusability: The enzyme can be recovered and used many times.
-
Stability: Often more resistant to pH/temperature changes.
-
Product Purity: The enzyme does not contaminate the liquid product (continuous flow systems).
Diffusion Limitations: When immobilized, the substrate must diffuse to the support. If the reaction is very fast, diffusion becomes the rate-limiting step (mass transfer controls the speed, not the enzyme reaction).
Part 3: Microbial Growth Kinetics
While enzymes follow Michaelis-Menten, whole cells follow Monod Kinetics .
3.1 The Monod Equation (Cell Growth)
The specific growth rate (μ) of microbes depends on the limiting nutrient concentration.
μ=μmax[S]Ks+[S]
-
μ: Specific growth rate (h⁻¹)
-
μmax: Maximum growth rate when substrate is abundant.
-
Ks: Substrate affinity constant (analogous to Km).
Key Takeaway: The Monod equation is structurally identical to Michaelis-Menten, but it describes cell growth rather than an enzymatic reaction.
3.2 Stoichiometry and Yields
Stoichiometry tracks how much substrate (food) converts into cells (biomass) vs. product (desired chemical) .
Substrate→CellBiomass (X)+Product (P)+CO2+Heat
Key Yield Coefficients:
| Coefficient | Formula | Interpretation |
|---|---|---|
| YX/S (Biomass yield) | ΔBiomass/ΔSubstrate | How efficiently cells turn sugar into more cells (g cells/g substrate). |
| YP/S (Product yield) | ΔProduct/ΔSubstrate | How efficiently substrate turns into the product (g product/g substrate). |
3.3 The Maintenance Energy
Not all consumed substrate is used for growth. A portion is used for maintenance (cell repair, motility, osmoregulation).
qS=μYX/Smax+m
Where m is the maintenance coefficient. When μ is low, most energy goes to maintenance.
Part 4: Bioreactor Design (The “Factory Floor”)
Bioreactors are containment vessels designed to provide a controlled environment for cell growth .
4.1 Basic Bioreactor Operation Modes
| Mode | Process | Cell Growth | Product Profile | Use Case |
|---|---|---|---|---|
| Batch | All nutrients added at start. Nothing added/removed until end. | Exponential phase → Stationary phase. | High concentration at the end. | Lab scale, specialty chemicals (wine, beer). |
| Fed-Batch | Nutrients added periodically. | Growth controlled (avoid inhibition). | Highest cell density achievable. | Most common industrial mode (Antibiotics, amino acids). |
| Continuous (Chemostat) | Fresh media added continuously; spent broth removed simultaneously. | Steady-state growth (μ=D, dilution rate). | Constant product concentration. | Wastewater treatment, research. |
4.2 Mass Transfer: The Oxygen Challenge
Most bioprocesses require oxygen (aerobic). Oxygen has poor solubility in water, so getting it from air bubbles to the cell is often the rate-limiting step.
Oxygen Transfer Rate (OTR):
OTR=kLa⋅(C∗−CL)
-
kLa: Volumetric mass transfer coefficient (depends on mixer speed, air flow, bubble size). Engineers try to maximize this.
-
(C∗−CL): The “driving force” (Difference between saturation concentration and actual concentration).
4.3 Sterilization
Contamination (presence of unwanted microbes) ruins a bioprocess.
-
Media Sterilization: Usually done by steam under pressure (autoclaving, or continuous steam injection for large tanks) .
-
Air Sterilization: Air fed to the bioreactor is passed through HEPA filters or depth filters.
Part 5: Downstream Processing (Recovery)
Once the reaction is complete, the product must be extracted from the “soup” (broth). This is often the most expensive part of the process, especially for high-purity pharmaceuticals .
5.1 Unit Operations for Recovery
| Stage | Operation | Function | Example Product |
|---|---|---|---|
| Solid-Liquid Separation | Centrifugation / Filtration | Removes cells (biomass) from liquid (broth). | Harvesting yeast. |
| Cell Disruption | Homogenization (High pressure) | Bursting cells to release intracellular products (if product is inside cell). | Releasing insulin from E. coli. |
| Concentration | Ultrafiltration (UF) | Uses membranes to concentrate proteins and remove water. | Concentrating antibody solution. |
| Purification | Chromatography | Separates the target molecule from contaminants based on charge, size, or binding affinity. | Producing 99.9% pure monoclonal antibodies. |
| Final Formulation | Spray Drying / Lyophilization | Turns liquid product into stable powder. | Dry powdered enzymes or vaccines. |
📝 Quick Reference Sheet
| Topic | Key Formula/Model | Critical Parameter |
|---|---|---|
| Enzyme Kinetics | v=Vmax[S]/(Km+[S]) | Km (affinity) |
| Cell Growth | μ=μmax[S]/(Ks+[S]) | μmax (max growth rate) |
| Continuous Culture | D=F/V (Dilution rate) | Steady-state: μ=D |
| Oxygen Transfer | OTR=kLa(C∗−CL) | kLa (Mixing efficiency) |
| Yield | YP/S=Product Made/Substrate Used | Economics (Cost of raw materials vs. Value of product) |
🌟 Key Takeaways
-
Biochemical Engineering is about Scale: Taking a reaction from a test tube (mL) to a factory (m³).
-
Kinetics are Non-Linear: Unlike chemical reactions, biological rates are limited by saturation (Monod/Michaelis-Menten). Doubling the food does not always double the output.
-
Oxygen is the Bottleneck: Aerobic fermenters are primarily designed for mixing and oxygen transfer, not just holding liquid.
-
Continuous is Efficient, Batch is Safe: Continuous (chemostat) is great for making ethanol or treating sewage, but Batch/Fed-Batch is preferred for pharmaceuticals to prevent genetic mutations.
-
Downstream Processing costs dominate: For high-value drugs (like vaccines), the bioreactor is often the cheaper part; purification using chromatography is the major expense.
Environmental and Health Biotechnology – Complete Study Notes
Part 1: Introduction to Environmental and Health Biotechnology
1.1 Definition of Environmental Biotechnology
Environmental biotechnology is a multidisciplinary field that leverages biological systems (microorganisms, plants, and their enzymes) to address environmental challenges, including pollution prevention, waste treatment, and ecosystem restoration . It integrates aspects of environmental engineering, biochemistry, and microbiology to repair contaminated ecosystems and promote sustainable practices .
The primary goal of environmental biotechnology is to create a better balance between human development and the natural environment by using biological processes to control contamination and treat waste .
1.2 Definition of Health Biotechnology
Health biotechnology (also called medical or biohealth science) applies biological principles and techniques to human health, encompassing genomics, proteomics, bioinformatics, regenerative medicine, drug and vaccine discovery, and molecular diagnostics . It encompasses the study of human biology, microbiology, biochemistry, and molecular biology to address problems impacting human health .
1.3 Historical Development
| Period | Development |
|---|---|
| Pre-Industrial | Communities used natural processes for sewage treatment and composting |
| 1960s-1970s | Chemical pollution came under public scrutiny (DDT, mercury poisoning, oil spills) |
| 1970s | Environmental regulations developed; environmental biotechnology emerged as a field |
| 1992 | UN Conference in Rio recognized environmental biotechnology as crucial for sustainable development |
| 1990s-2000s | Rapid advancement in genetic engineering; expansion into soil contamination, solid waste treatment, air purification |
Part 2: Environmental Biotechnology – Core Principles
2.1 Fundamental Concepts
Environmental biotechnology operates on four basic approaches :
| Approach | Description |
|---|---|
| Bioremediation | Using microorganisms to degrade or remove contaminants |
| Prevention | Developing processes that prevent pollution before it occurs |
| Detection & Monitoring | Using biosensors and bioassays to identify contaminants |
| Genetic Engineering | Enhancing microbial capabilities for pollutant degradation |
2.2 Bioremediation Technologies
Bioremediation is classified based on where treatment occurs and how it is stimulated.
In Situ vs. Ex Situ Remediation
| Type | Location | Advantages | Disadvantages |
|---|---|---|---|
| In situ | On-site treatment | No excavation; minimal disturbance | Slower; less controllable |
| Ex situ | Off-site treatment | Better control; faster | Excavation required; higher cost |
Bioremediation Enhancement Methods
| Method | Description | Application |
|---|---|---|
| Natural attenuation | Unassisted natural degradation | Low contamination levels |
| Biostimulation | Adding nutrients, oxygen, or substrates to stimulate native microbes | Nutrient-poor contaminated sites |
| Bioaugmentation | Introducing specific microorganisms to enhance degradation | Sites lacking appropriate microbial populations |
| Bioenrichment | Adding nutrients or oxygen to increase breakdown | Petroleum-contaminated sites |
2.3 Phytoremediation
Phytoremediation uses plants to remediate contaminated soil and water .
Mechanisms of Phytoremediation:
| Mechanism | Process | Target Contaminants |
|---|---|---|
| Phytoextraction | Plants absorb and accumulate contaminants in harvestable tissues | Heavy metals (Cd, Pb, Ni, Zn) |
| Phytostabilization | Plants immobilize contaminants in soil | Heavy metals |
| Phytodegradation | Plants break down organic contaminants | Organic pollutants, xenobiotics |
| Rhizodegradation | Plant roots stimulate microbial degradation in rhizosphere | Petroleum hydrocarbons, PAHs |
| Phytovolatilization | Plants take up and release volatile contaminants | Mercury, selenium |
| Phytomining | Harvesting plants to extract valuable metals | Nickel, gold, thallium |
2.4 Biosensors and Biomonitoring
Biosensors are devices that detect and measure chemical substances in the environment and translate that information into data .
| Biosensor Type | Detection Method | Applications |
|---|---|---|
| Electrochemical | Measures electrical changes | Heavy metals, pesticides |
| Optical | Measures light absorption or fluorescence | Pathogens, toxins |
| Microbial biosensors | Uses whole-cell microorganisms | BOD, toxicity screening |
| Enzyme-based | Uses immobilized enzymes | Glucose, pesticides, herbicides |
Bioassays measure contaminant concentration by observing effects on living organisms, essential for assessing real and potential pollution effects .
Part 3: Key Applications of Environmental Biotechnology
3.1 Bioremediation Applications
Petroleum Hydrocarbons:
-
Oil spills (marine and terrestrial)
-
Gasoline and diesel contamination
-
Biostimulation with nitrogen and phosphorus fertilizers
Chlorinated Solvents:
-
TCE, PCE in groundwater
-
Anaerobic dechlorination by Dehalococcoides species
Heavy Metals:
-
Biosorption using microbial biomass
-
Bioleaching for metal recovery
-
Phytoremediation of mine tailings
Pesticides:
-
Organophosphate degradation
-
Herbicide breakdown in agricultural soils
3.2 Wastewater Treatment
Wastewater treatment uses biological processes to remove organic matter and nutrients .
Conventional Treatment Systems:
| System | Process | Application |
|---|---|---|
| Activated sludge | Aerobic microbial flocs | Municipal wastewater |
| Trickling filters | Biofilm on solid media | Secondary treatment |
| Anaerobic digesters | Methanogenic bacteria | Sludge treatment; industrial wastewater |
| Lagoons | Natural aeration and settling | Small communities |
| Biofilm reactors | Attached growth systems | High-rate treatment |
| Membrane bioreactors (MBR) | Membrane filtration + biological treatment | Advanced treatment; water reuse |
3.3 Bioenergy Production
Biofuels :
| Fuel | Feedstock | Process | Products |
|---|---|---|---|
| Biodiesel | Vegetable oils, animal fats | Transesterification | Methyl esters, glycerin |
| Biogas | Organic waste | Anaerobic digestion | Methane (CH₄), CO₂ |
| Biohydrogen | Organic substrates | Dark fermentation; photofermentation | Hydrogen (H₂) |
| Bioethanol | Corn, sugarcane, lignocellulose | Fermentation | Ethanol |
Bioelectrochemical Systems :
| System | Description | Output |
|---|---|---|
| Microbial Fuel Cell (MFC) | Bacteria generate electricity from organic matter | Electricity |
| Plant Microbial Fuel Cell (PMFC) | Living plants + MFC | Continuous electricity |
| Microbial Electrolysis Cell (MEC) | Hydrogen production with small voltage input | Hydrogen |
3.4 Bioprocessing and Resource Recovery
Bioprocessing uses living cells or organisms to produce specific outcomes :
| Process | Application |
|---|---|
| Microbial Enhanced Oil Recovery (MEOR) | Extracting additional oil from reservoirs |
| Biodesulfurization | Removing sulfur from fossil fuels |
| Biological treatment of polluted air | Biofilters, bioscrubbers |
| Conversion of pollutants to useful products | Fertilizers, bioplastics, green energy |
| Bioelectrochemical systems (BES) | Fuel production from biodegradable organic matter |
3.5 Microalgal Biotechnology
Microalgae are used in environmental applications, including :
| Application | Process |
|---|---|
| Wastewater treatment | Nutrient removal (N, P) |
| CO₂ bioremediation | Carbon capture from flue gas |
| Biofuel production | Biodiesel from algal lipids |
| High-value products | Pigments, omega-3 fatty acids |
| Biorefinery concept | Integrated production of multiple products from algal biomass |
3.6 Biofilm Control
Biofilms (microbial slime layers) occur on surfaces in aqueous environments. They are classified as beneficial, neutral, or harmful depending on context .
| Biofilm Type | Examples | Management |
|---|---|---|
| Beneficial | Wastewater treatment biofilms, bioremediation biofilms | Promote growth |
| Neutral | Natural aquatic biofilms | Monitor |
| Harmful | Pipe corrosion, medical device infections, biofouling | Control using physical/chemical methods |
Part 4: Health Biotechnology
4.1 Molecular Diagnostics
Techniques :
| Technique | Application | Advantages |
|---|---|---|
| PCR and RT-PCR | Pathogen detection, gene expression | High sensitivity, specificity |
| Real-time PCR (qPCR) | Quantification of pathogens | Quantitative results |
| Multiplex PCR | Multiple pathogen detection | Time and cost efficiency |
| DNA sequencing | Pathogen identification, resistance genes | Comprehensive analysis |
| Microarrays | Multiple gene expression analysis | High-throughput |
| Biosensors | Point-of-care diagnostics | Rapid, portable |
Molecular Diagnostics Applications:
-
Infectious disease diagnosis (emerging diseases, antimicrobial resistance monitoring)
-
Genetic disorder screening
-
Cancer biomarker detection
-
Pharmacogenomics (personalized medicine)
4.2 Drug Discovery and Development
Pharmaceutical Biotechnology :
| Area | Examples |
|---|---|
| Biopharmaceuticals | Therapeutic proteins, monoclonal antibodies, cytokines, growth factors |
| Vaccines | Recombinant vaccines, DNA vaccines, mRNA vaccines |
| Antimicrobial peptides | Novel antibiotics, antifungal agents |
| Phage therapy | Bacteriophages for antibiotic-resistant infections |
| Antisense antibiotics | Gene-silencing antimicrobials |
4.3 Genomics and Proteomics
Genomics:
-
Whole-genome sequencing of pathogens
-
Identification of virulence factors
-
Antimicrobial resistance gene detection
-
Host-pathogen interaction studies
Proteomics:
-
Protein structure and function analysis
-
Biomarker discovery for disease diagnosis
-
Drug target identification
Bioinformatics:
-
Database searching (NCBI, BLAST)
-
Sequence alignment (Clustal)
-
Primer design
-
Phylogenetic analysis
4.4 Regenerative Medicine and Drug Delivery
Regenerative Medicine :
| Application | Technology |
|---|---|
| Tissue engineering | Scaffolds, cell therapy, growth factors |
| Bone regeneration | Injectable hydrogels, stem cells |
| Wound healing | Bioactive peptides, nanofiber dressings |
| Stem cell therapy | Mesenchymal stem cells for various conditions |
Drug Delivery Systems :
| System | Description | Applications |
|---|---|---|
| Liposomes | Phospholipid vesicles | Cancer therapy, vaccine delivery |
| PLGA nanoparticles | Biodegradable polymer | Controlled release |
| Protein-based carriers | Natural protein formulations | Targeted delivery |
| Nanogels | Crosslinked polymer networks | Imaginology, cancer therapy |
| Hydrogels | Water-swollen polymer networks | Bone regeneration, wound healing |
4.5 Infectious Disease Research
Key Research Areas :
| Area | Focus |
|---|---|
| Pathogen biology | Understanding pathogen life cycles and virulence mechanisms |
| Host-pathogen interactions | Immune response, disease progression |
| Antimicrobial resistance | Resistance mechanisms, novel therapeutics |
| Vaccine development | Subunit, recombinant, and nucleic acid vaccines |
| Emerging diseases | COVID-19, Ebola, Zika, preparedness |
4.6 Non-Communicable Diseases (NCDs)
Research Areas :
| NCD Category | Biotechnological Approaches |
|---|---|
| Cancer | Targeted therapies, immunotherapies, CAR-T cells, biomarkers for early detection |
| Neurodegenerative diseases | ALS, Huntington’s, Parkinson’s – protein structure studies, drug targets |
| Metabolic disorders | Gene therapy, enzyme replacement, microbiome modulation |
| Autoimmune diseases | Monoclonal antibodies, immunomodulators |
Part 5: Advanced Topics
5.1 Genetic Engineering for Environmental Applications
Genetically Engineered Microbes (GEM) are created to enhance pollutant degradation capabilities .
| Modification | Purpose | Target Pollutants |
|---|---|---|
| Pathway enhancement | Increase degradation rate | Chlorinated compounds, PAHs |
| Pathway addition | Degrade novel compounds | Xenobiotics, synthetic chemicals |
| Biosensor construction | Detect specific pollutants | Heavy metals, toxins |
| Metal-binding proteins | Enhanced biosorption | Heavy metals |
Biosafety Considerations:
-
Containment strategies
-
Environmental risk assessment
-
Regulatory compliance
5.2 Synthetic Biology for Health
Synthetic biology applications in health biotechnology include :
| Application | Approach |
|---|---|
| Viral nanocarriers | Engineered viral particles for cancer cell targeting |
| Aptamers | Nucleic acid molecules for cancer cell recognition |
| Phage-based nanocarriers | Cancer treatment and diagnosis |
| Gene circuits | Engineered cellular systems for therapeutic production |
5.3 Nanotechnology in Biotechnology
Environmental Nanotechnology :
| Application | Technology |
|---|---|
| Pollutant detection | Nanosensors, nanobiosensors |
| Water treatment | Nanofiltration, photocatalytic nanoparticles |
| Remediation | Nanoscale zero-valent iron (nZVI) |
| Biomining | Nanoparticle-enhanced metal recovery |
Part 6: Bioethics and Intellectual Property
6.1 Biosafety and Bioethics
Key Considerations :
| Issue | Questions |
|---|---|
| GMO release | Environmental impact assessment; containment measures |
| Human genetic modification | Germline vs. somatic; consent; equity |
| Clinical trials | Informed consent; risk-benefit analysis |
| Data privacy | Genetic information protection |
| Access to treatments | Equitable distribution of biotechnological therapies |
6.2 Intellectual Property Rights (IPR)
IPR in Biotechnology :
| Type | Subject Matter | Duration |
|---|---|---|
| Patents | Novel biotechnological inventions, GMOs, diagnostic methods | 20 years |
| Copyrights | Software, databases, publications | Life + 70 years |
| Trade secrets | Proprietary processes, formulations | Indefinite |
| Plant variety rights | New plant varieties | 20-25 years |
IPR Issues in Environmental Biotechnology:
-
Patenting of naturally occurring microorganisms
-
Benefit-sharing with source countries
-
Access to patented technologies for environmental remediation
Quick Revision Tables
Table 1: Environmental vs. Health Biotechnology
| Aspect | Environmental Biotechnology | Health Biotechnology |
|---|---|---|
| Primary focus | Pollution control, waste treatment, ecosystem restoration | Human disease diagnosis, treatment, prevention |
| Key organisms | Bacteria, fungi, plants, algae | Human cells, pathogens, animal models |
| Products | Clean water, biofuels, bioplastics, remediated soil | Vaccines, therapeutics, diagnostics |
| Techniques | Bioremediation, bioprocessing, bioaugmentation | Genomics, proteomics, drug delivery |
Table 2: Environmental Biotechnology Applications by Medium
| Medium | Contaminants | Treatment Methods |
|---|---|---|
| Soil | Heavy metals, petroleum, pesticides | Phytoremediation, bioaugmentation, biosparging |
| Water | Organics, nutrients, pathogens | Activated sludge, biofilms, membrane bioreactors |
| Air | VOCs, odors, H₂S | Biofilters, bioscrubbers |
| Groundwater | Chlorinated solvents, fuels | In situ bioremediation, monitored natural attenuation |
Table 3: Common Molecular Techniques
| Technique | Purpose | Detection Limit |
|---|---|---|
| PCR | DNA amplification | Single copy |
| qPCR | Quantitative DNA detection | 10-100 copies |
| RT-PCR | RNA detection (gene expression) | Low abundance transcripts |
| Sequencing | DNA/RNA base identification | Single nucleotide |
| FISH | Spatial localization of microbes | 10³-10⁴ cells/mL |
| Microarray | High-throughput expression | Moderate |
Exam Tips
-
Understand the core definition: Environmental biotechnology uses biological systems to address environmental problems; health biotechnology applies biological principles to human health.
-
Know the four approaches to environmental biotechnology: bioremediation, prevention, detection/monitoring, and genetic engineering.
-
Distinguish between in situ vs. ex situ remediation, biostimulation vs. bioaugmentation, and phytoremediation mechanisms.
-
Be familiar with molecular techniques for microbial community analysis (16S rRNA gene, PCR, sequencing, bioinformatics).
-
Understand bioenergy production from organic waste (biogas, biohydrogen, microbial fuel cells).
-
Know the applications of microalgae in wastewater treatment, CO₂ capture, and biofuel production.
-
For health biotechnology: Be familiar with molecular diagnostics, drug delivery systems, vaccine development, and regenerative medicine.
-
Know key environmental legislation and its impact on development of environmental biotechnology.




